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Abstract 
 
An innovative drug delivery system for inner ear therapy is based on the use of nanoparticles (NPs): 
they can be considered good carriers for therapeutic drugs within the inner ear, because they 
increase drug diffusion and are detected in all parts of the cochlea when applied near the round 
window. In this study liquid crystalline NPs based on glycerol monooleate were developed and 
conjugated with two hydrophobic drugs, coenzyme Q10 and dexamethasone, already used for inner 
ear therapies but limited in their efficacy by low solubility and bioavailability. These conjugated 
NPs were tested in vitro on two different cell lines, as models of the inner ear cell populations: 
thePC12 cells, neural-like cells used as a model of neuronal differentiation, and OC-k3, derived 
from the organ of Corti of transgenic mice as a model of inner ear sensory cells. The NPs 
conjugated with coenzyme Q10 or dexamethasone were tested against cisplatin (cis-
diamminedichloroplatinum(II)), a cytotoxic agent widely used for treatment of solid tumors. 
Although effective as antitumor agent, cisplatin induces serious collateral effects, among which 
ototoxicity on the auditory nerve, the stria vascularis and hair cells. The results showed that NPs 
conjugated with drugs are well tolerated by both cells lines and are uptaken by cells in the first few 
hours after treatment, delivering the conjugated compounds inside the cells. Moreover, NPs 
conjugated with dexamethasone were able to counteract damages caused by cisplatin, preventing 
apoptosis in OC-k3 cells, and increased the concentration of drug uptaken by the cells compared to 
the free drug treatment. Based on these results, NPs have an interesting potential as inner ear drug 
delivery systems. 
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1 Introduction 
 
1.1 The auditory system: anatomy and physiology 
 
1.1.1 Anatomy of the ear 
 
The auditory system enables the hearing perception (hearing function) and the regulation of the 
sense of balance (vestibular function). It is anatomically divided into three parts: outer, middle and 
inner ear. The outer part is composed of the pinna and the auditory canal. At the bottom of the canal 
the tympanic membrane (eardrum) creates a barrier protecting the middle ear. The middle ear 
consists of the tympanic cavity, containing the ossicular chain composed by the malleus, the incus 
and the stapes. The Eustachian tube opens in the middle ear and allows the ventilation of the 
tympanic cavity via the nasopharynx (1). The outer ear and middle ear redirect and amplify the 
sound vibration coming from the outside towards the inner ear, connected to the tympanic cavity by 
the round window membrane (RWM) and the oval window (2). The inner ear is inserted in the 
petrous part of the temporal bone and contains the organ of sensorineural hearing (the cochlea), the 
organs of balance (utricle and saccule) and the semicircular canals (1) (Fig. 1.1). 
 
Fig. 1.1. Anatomical scheme of the human ear (redrawn from: ©1997 Encyclopedia Britannica, 
Inc.). 
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1.1.2 The cochlea 
 
The cochlea is a coiled tube, about 30 mm long in humans, making 2 and ¾ turns around a mass of 
fibrous tissue called modiolus. The internal structure of the cochlea is composed of three fluid filled 
compartments located inside the petrous temporal bone. The middle channel, called scala media or 
cochlear duct, is filled with endolymph, while the lower and upper compartments, respectively 
called scala tympani and scala vestibuli, are both filled with perilymph. Scala tympani and scala 
vestibuli are connected at the apex of the cochlea through a passage known as helicotrema (3) (Fig. 
1.2). The scala media contains the organ of Corti, responsible for the transduction of the auditory 
signal to the brain; the organ is shielded above by the Reissner’s membrane and at the bottom lays 
on the basilar membrane. The scala media is anchored to the outer bony structure by the spiral 
ligament, made of connective tissue. The ligament is highly vascularised by a tissue named stria 
vascularis. 
 
 
Fig. 1.2. Section of the cochlea (redrawn from: ©1997 Encyclopedia Britannica, Inc.). 
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1.1.3 The organ of Corti 
 
The organ of Corti is composed of two different kinds of cells: the sensory ones, called hair cells 
because of the presence of stereocilia at the cellular apex, and the supporting cells (Fig. 1.3). Other 
cells rich in cytoskeleton, called pillar cells, cover the cochlear duct. Hair cells are arranged in 
longitudinal rows, divided in one row of inner hair cells and three rows of outer hair cells. The inner 
hair cells differ from the outer ones in number (in humans the proportion is about 1:10) and in shape 
and structure of the stereocilia. Above the organ of Corti there is the tectorial membrane, in direct 
contact with the stereocilia. The hair cells are connected to the central nervous system by afferent 
nerve fibers projecting to the auditory cortex. A long nervous ganglion, called spiral ganglion, is 
located inside the modiulus: it is made of cell bodies of the neurons related to the cochlea, whose 
combined processes form the acoustic nerve. Together with the vestibular nerve, the spiral ganglion 
forms the vestibulocochlear nerve (eighth cranial nerve). About 95% of the nerve fibers of the spiral 
ganglion individually innervate the inner hair cells which are able to discriminate among incoming 
sound vibrations; the remaining 5% take multiple contacts with the outer hair cells, whose role is to 
increase the sound signal sensitivity (2).  
 
 
Fig. 1.3. Structure of the organ of Corti (redrawn from: ©1997 Encyclopedia Britannica, Inc.). 
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1.1.4 Transmission of the acoustic signal 
 
In the auditory process, the acoustic waves are channelled by the pinna into the auditory canal, 
inducing the vibration of the eardrum. The vibrations cause the movement of the ossicular chain, 
which transfers the mechanical pressure waves to the inner ear fluids through the oval window. 
During their passage, the pressure waves cause vibrations of the basilar membrane and thus of the 
organ of Corti. The resulting vibrations of stereocilia of the hair cells are responsible for acoustic 
signal transduction: the mechanical waves are transformed into an electric signal by inducing a 
variation of intracellular potential leading to the release of neurotransmitters. The signal is then 
transmitted via the cochlear nerve to the auditory cortex to be processed (4). The hair cells and the 
neurons of the inner ear are in a state of terminal differentiation and have lost the ability to 
regenerate or proliferate: thus, once the inner ear tissue is damaged by an external agent, the loss of 
function in the auditory system becomes permanent (2).  
 
1.1.5 Ototoxicity 
 
The medical condition of unilateral or bilateral hearing impairment is defined as hypoacusis 
(hearing loss): it is called transmission hypoacusis when it is related to alterations of the external or 
middle ear and sensorineural hypoacusis when it is related to the inner ear. The latter is classified 
according to whether the deficit concerns the cochlea (cochlear hearing loss) or the related nerve 
pathway (retrocochlear hearing loss) (5). According to World Health Organization data published 
on March 2015, about 360 million people worldwide have disabling hearing loss, referring to 
hearing loss greater than 40 decibels (dB) in the better hearing ear in adults and greater than 30 dB 
in the better hearing ear in children. According to the same data, one-third of people over 65 years 
of age are affected by disabling hearing loss caused by congenital or hereditary factors or induced 
by exogenous ones. Exogenous hearing loss can be caused by numerous stress factors such as noise, 
trauma, infections and ototoxic effects of drugs. Among the drugs there are substances which cause 
the loss or dysfunction of the auditory cells (hair cells and neurons), and the induced damage can be 
reversible or permanent (2). Among pharmacological drugs widely used in clinical practice that 
cause a loss of the hearing function there is cisplatin. 
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1.2 Cisplatin 
 
1.2.1 Structure and characteristics 
 
Cisplatin ((SP-4-2)-diamminedichloroplatinum(II)) (CDDP) is a chemotherapeutic agent belonging 
to the class of platinum containing anti-cancer drugs. It was the first platinum antitumor drug 
introduced in clinical practice (6) and is still one of the most powerful and widely used agent to 
treat solid tumors affecting head, neck, lungs, oesophagus, stomach and genitourinary tract (7, 8). 
The structure of the CDDP includes a central platinum atom with four ligands, two amino groups 
and two hydrochloric groups (Fig. 1.4): when the last two groups are disposed in cis conformation, 
the molecule exhibits chemotherapeutic activity (9). The cellular uptake of CDDP, although not 
fully understood, is thought to occur because of passive diffusion via transmembrane channels and 
facilitated diffusion processes (10). Once inside the cells, the two chlorine atoms are substituted 
with two molecules of water, forming a monohydrate complex: this turns the CDDP into a very 
reactive and cytotoxic molecule, able to interact with the cellular proteins, the phospholipid 
membrane, the cytoskeleton microfilaments, RNA, nuclear and mitochondrial DNA (11). All these 
effects may induce cell death by apoptosis, which is at the base of the antitumor role of CDDP (12). 
 
                 
Fig. 1.4. A. Structure of cisplatin ((SP-4-2)-diamminedichloroplatinum(II)). B. cis- conformation of 
cisplatin (redrawn from Goodsell, 2006).  
 
1.2.2 Cisplatin ototoxicity and cytotoxicity 
 
The clinical administration of CDDP induces severe dose-dependent side effects, including 
neurotoxicity, nephrotoxicity and ototoxicity. A major limitation of the chemotherapy is also the 
A B 
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development of a serious drug resistance of the cancer cells (13). In detail, the CDDP ototoxicity is 
dose-dependent, affecting the hearing capacity and inducing the occurrence of tinnitus in patients 
(14). However, there is a high variability of individual response due to metabolism, genetic factors, 
age, combination with other drugs and pre-existing hearing problems (14, 15). CDDP affects the 
cell population of the organ of Corti, the spiral ganglion and the stria vascularis, causing 
morphological alterations and cell death. The treatment with CDDP induces first the death of the 
hair cells of the basal turn of the cochlea and the neurons connected to them (15-19). 
The mechanism of CDDP cytotoxicity, although not fully understood, includes the interaction of the 
drug with DNA and the formation of DNA adducts (7): these bonds cause inhibition of the nucleic 
acid production (7) and the arrest of the cell cycle (20-23). Some studies have also shown that 
CDDP induces mitochondrial dysfunction and production of reactive oxygen species (ROS) in the 
cochlear cell population (24-29): in the adult inner ear, where the cells are mostly post-mitotic, the 
CDDP toxicity could be less related to DNA damages, but ROS production could play a major role 
in the mechanism of ototoxicity (30). The increased ROS production could be caused by a decrease 
of antioxidant enzymes or by direct ROS activation: CDDP administration has been recently 
associated to a decrease of activity of superoxide dismutase, catalase, glutathione peroxidase and 
reductase in the cochlea (16) and to higher levels of superoxide anion (31) and nitric oxide (32). 
The inhibition of antioxidants and the overproduction of ROS may increase calcium concentration 
in hair cells and in cochlear neurons, impairing the signal transmission and triggering the apoptotic 
process (25, 33). 
 
1.3 The apoptotic process 
 
Apoptosis, or programmed cell death, is an ATP-dependent physiological cell process (34), highly 
conserved (35) and aimed to regulation and maintenance of cell populations and development of the 
organism (36). Apoptosis is characterized by an ordered sequence of events: in the initial step the 
cell undergoes a shrinkage due to cytoskeleton degradation, leading to the loss of some membrane 
properties and to detachment from nearby cells. The next step is the condensation of the chromatin, 
followed by nuclear envelope discontinuity and chromatin fragmentation by endonucleases. Finally 
the cell organelles are degraded and the cells undergo a process called blebbing, a division into 
small apoptotic bodies, engulfed by phagocytosis by nearby macrophages without any inflammatory 
reaction (37). 
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The initial phase of the apoptotic process can be regulated by two different signal pathways, called 
extrinsic (receptor based) and intrinsic (mitochondrial). Both ways can be regulated or reversed, and 
converge in the late phase of apoptosis by activating the same effector enzymes (37). 
The extrinsic apoptotic pathway is activated by the cell membrane death receptors, which transmit 
intracellular pro-apoptotic signals as a consequence of binding with specific ligands (38). The 
subsequent steps are mediated by the cytoplasmic part of the activated receptor: a highly conserved 
sequence called “death domain” recruits and binds the cytoplasmic protein Fas associated to death 
domain (FADD), forming a complex called “death inducing signalling complex” (DISC). The DISC 
proceeds by activating the initiator of the apoptotic cascade, pro-caspase 8, that in turn activates the 
effector caspases (39). 
The apoptotic signal can be either amplified or directly activated in the intrinsic apoptotic pathway 
in mitochondria (40, 41): the link between the extrinsic and intrinsic way is the BH3 interacting- 
domain death protein (Bid), belonging to the Bcl-2 family: Bid is cleaved by caspase 8 and its 
truncated form translocates to the mitochondria (42). Together with other mitochondrial proteins, 
such as BAX, it induces the release of cytochrome c and other pro-apoptotic factors in the 
cytoplasm. 
The protein Bid acts by directly activating BAX, that accumulates near the mitochondrial 
membrane and causes the opening of the mitochondrial voltage-dependent channels, favouring the 
leakage of cytochrome c (43). The expression of Bid and BAX is upregulated by numerous factors, 
among which p53, an antitumor protein and transcriptional factor overexpressed in response to 
cellular stress (44). 
The activation of the intrinsic pathway of apoptosis involves the protein procaspase 9 (45): once 
cytochrome c is released from mitochondria to cytoplasm, it induces the formation of a pro-
apoptotic protein complex, the apoptosome, which directly cleaves the procaspase 9 (46). When 
caspase 9, the initiator of the apoptotic intrinsic pathway, is activated, it exerts proteolitic activity 
on the effector caspases (3, 6, 7) (47), leading the cell to the final phase of the apoptosis. Caspase 3 
acts in the late apoptotic stage by regulating the activity of deoxyribonucleases (DNases) 
responsible for DNA degradation, such as poly (ADP-ribose) polymerase (PARP), inducing 
morphological changes of the nucleus and of the entire cell (48, 49).  
Cisplatin (CDDP) induces cytotoxic effects on DNA and causes signal transduction in several 
molecular pathways, including those of p53 and of the family of mitogen-activated protein kinases 
(MAPK), which lead the cell to apoptosis (50). An overexpression of p53 has been shown to 
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activate the apoptotic cascade including Fas/FADD, caspase 8 and caspase 3 (51, 52). The MAPK is 
a family of numerous protein kinases involved in cell metabolism and proliferation (53, 54); the 
overexpression of the subfamily of extracellular signal-regulated kinases (ERK) has been associated 
to the effects of CDDP-induced apoptosis, the release of cytochrome c and the activation of caspase 
9 and 3 (13) (Fig. 1.5). When the DNA damage induced by CDDP becomes irreversible, a 
concomitant activation of the intrinsic apoptotic pathway has been observed, with translocation of 
BAX into the mitochondria and activation of caspase 9 and 3 (13, 55). 
 
 
Fig. 1.5. Model of CDDP-induced signaling pathways leading to ERK activation and apoptosis 
(redrawn from: Wang et al., 2000). 
 
1.4 Treatment of drug-induced ototoxicity 
 
Several compounds have been tested in clinical practice and basic research against drug-induced 
ototoxicity, in order to reduce or mitigate cellular stress, ROS production and/or DNA damages. 
Among these compounds there are the coenzyme Q10 and the dexamethasone. 
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1.4.1 Coenzyme Q10 
 
Coenzyme Q10, also called ubichinone (2, 3-dimethoxy-5-methyl-6-decaprenyl-1,4 benzoquinone, 
CoQ10), ubiquitous molecule in human and animal body, is a vitamin-like antioxidant (Fig. 1.6) 
involved in electron transport along the mitochondrial respiratory chain. It reacts with ROS and 
lipoperoxidases preventing damages to cells and tissues (56-58). As a ROS scavenger, CoQ10 may 
be used as antiapoptotic agent (59): it works by inhibiting the mitochondrial membrane 
depolarization, thus the consequent release of cytochrome c into cytoplasm and the activation of 
procaspases 9 and 3 (60). In animal models the antioxidants can be administrated locally or 
systemically (61): the local administration of antioxidants through the round window in vivo 
increases the glutathione level and reduces the effects of noise induced hearing loss (62). The 
administration of antioxidants before noise exposure significantly reduces the threshold shift and 
the death of hair cells (63). 
 
 
Fig. 1.6. Structure of coenzyme Q10 (2, 3-dimethoxy-5-methyl-6-decaprenyl-1,4 benzoquinone, 
CoQ10) (retrieved from http://www.sigmaaldrich.com/catalog/product/sigma/c9538?lang=it& 
region=IT). 
 
1.4.2 Dexamethasone 
 
Dexamethasone is a synthetic drug belonging to the family of the glucocorticoids and used for a 
wide variety of clinical therapies (Fig. 1.7). In inner ear therapies, steroids are mostly administered 
via the systemic route, but in this way it is very difficult to reach the therapeutic concentration 
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within the inner ear because of the inner ear blood barrier (64). Moreover, the systemic use of high 
steroid doses causes numerous side effects to other organs. Dexamethasone has been administrated 
with local inner ear applications in cases of autoimmune diseases (65), sudden hearing loss (66) and 
currently for treatment of Meniere’s disease (67). Dexamethasone has been shown to reduce the 
toxicity caused by administration of aminoglycosides: it has been reported that glucocorticoids may 
reduce cell stress and inner ear cell death rate in vivo on Guinea pigs (68). In the same animal 
model, other studies verified that dexamethasone was able to reduce CDDP ototoxicity in vivo (69), 
induce overexpression of antioxidant enzymes (26) and reduce the levels of NADPH oxidase 3 
(NOX-3) (70). The in vitro treatment with dexamethasone affects the expression of MAPK 
pathway, with increased activation of Jun and p38 protein subfamilies, but not of the ERK 
subfamily (71).  
 
 
Fig. 1.7. Structure of dexamethasone (retrieved from: https://pubchem.ncbi.nlm.nih.gov/image/fl. 
html?cid=5743). 
 
1.5 Nanoparticles based systems for inner ear drug delivery 
 
The treatment of inner ear diseases through drug delivery (DD) faces numerous challenges (72) 
such as the limited blood flow to the inner ear (73), the presence of physical barriers acting as a 
selective filter for drug transportation from circulatory system to inner ear (74), the small size of the 
cochlea and its isolated anatomical position. Research in local drug applications and medications 
has recently attracted interest because it is a better and more effective treatment than the systemic 
one. Case studies involving antioxidants (56), steroids (75) and gentamicin in treatments for 
Meniere’s disease (76) have been documented, but these approaches have not yet been applied in 
clinical protocols due to the lack of controlled and targeted delivery systems. 
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Nanoparticles (NPs) are a possible option to improve existing therapeutic strategies (77). The NPs 
with size between 10 and 100 nm could be applied in biology and medicine as innovative DD 
system: this strategy could be more efficient and reduce drug-associated side effects because of the 
ability of NPs to deliver the therapeutic agent to the target site. Moreover, the controlled release of 
compounds conjugated to NPs results in a lower dose of drug required to achieve the therapeutic 
effects (78). 
The cochlea is a good model for studying NP-based DD because of its isolated structure and of the 
perilymph rheology that facilitates the distribution of administered compounds. The intratympanic 
delivery of NPs could be suitable to treat the induced hearing loss and prevent its progression when 
hair cells and spiral ganglion neurons are damaged (79). 
 
1.5.1 Ear barriers limiting drug intake 
 
The afflux of molecules and compounds in the inner ear is selectively regulated by a system of 
physical barriers: the round window membrane (RWM) and the blood inner ear barrier (BB) isolate 
the cochlea respectively from the middle ear and from the circulatory system (Fig 1.8). The RWM 
is a three-layer semi-permeable membrane composed of an outer epithelial cell layer, a middle 
connective layer and an inner connective layer facing the perilymph of the scala tympani (80). In 
humans, the variable thickness of RWM affects the response of patients to DD treatments. In animal 
models, the RWM has different thickness according to the species but its composition is similar 
(81). 
The RWM is the main passage for DD from the middle ear cavity to the cochlear perilymph. The 
passage of molecules across this membrane is influenced by its thickness, morphological integrity, 
inflammation and weight, but also by concentration, liposolubility and external charge of the 
therapeutic compound (82). The drugs deposited topically in the middle ear cavity are internalized 
by pinocytosis and transported to the perilymph through blood vessels or by diffusion. The direct 
application of drugs in the proximity of RWM is therefore a suitable approach for treatment of inner 
ear pathologies (83). 
The BB is a major barrier in the stria vascularis separating the cochlear tissues from the circulatory 
system (84, 85). Its main components are the endothelial capillaries whose cells are connected by 
tight junctions. The role of BB is to maintain the homeostasis of cochlear fluids and protect the 
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inner ear integrity. The BB acts as a physical and biochemical barrier through an efflux pump, the 
P-glycoprotein 1 (86), therefore it is considered a rate-limiting barrier in the passage of therapeutic 
agents from the circulatory system to the inner ear. However, the current knowledge about drug 
transportation processes through BB is limited (87). 
 
 
Fig. 1.8. Cochlear barriers. Image of Guinea pig cochlea in longitudinal section near the round 
window. RW, round window; BB, blood barrier. 
 
1.5.2 Administration routes for drug delivery to the inner ear 
 
To date the clinical protocols for inner ear therapies rely on systemic and local DD routes (Fig. 1.9). 
The systemic administration represents a classical route for DD, but in the inner ear only few drugs 
may reach the target site at therapeutic concentrations. High doses of systemic drugs often induce 
the development of side effects (88, 89). Systemic applications of nanoparticles in the inner ear 
have been recently investigated: poly(lactic-co-glycolic acid) NPs conjugated with rhodamine B 
and applied systemically were detected in the liver, but not in the cochlea (90). The limited 
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bioavailability of NPs after systemic administration could be due to the rapid clearance from the 
circulation in liver and spleen (91). 
Local administration appears more suitable for inner ear DD (19) because it allows a quick 
distribution of the drug inside the cochlea, improving delivery to the target site; it also requires 
lower drug doses, avoiding side effects (92). Two main routes are presently used for this purpose, 
the intratympanic (IT) or the intracochlear administration, but the second one is rarely performed 
because it is highly invasive and limited to surgery cases (93). On the contrary, the IT injection is 
minimally invasive and relies on passive diffusion of the active molecules through RWM. This 
technique does not cause trauma or hearing loss in patients or in the animal model. However, local 
delivery trials show a high variability in results (94) because of some key factors: 1) the drug 
clearance within the middle ear through the Eustachian tube; 2) the permeability of RWM; and 3) 
the residence time of the drug in contact with RWM (95). A method to reduce variability of results 
and increase the drug concentration in the perilymph could be to better control the residence time of 
the drug at close range with RWM, using specific delivery systems based on NPs (96). 
The NPs used in DD (also called nanocarriers or nanovectors) are artificial compounds with size 
below 1 µm, which should compensate for adverse drug properties such as low solubility, 
degradation and short half-life (1). The NPs may also be adapted to target a specific tissue of the 
inner ear. However, when injected in the middle ear as a liquid suspension, NPs will undergo 
clearance through the Eustachian tube (97), thus significantly reducing their residence time near 
RWM. The NPs suitable for DD systems should therefore increase the residence time, together with 
the ability to cross RWM and biocompatibility.  
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Fig. 1.9. Scheme of nanoparticle administration routes. Arrow, intratympanic route; arrowhead, 
intracochlear route: black by round window and white by cochleostomy. 
 
1.5.3 Liquid Crystalline NPs 
 
Lyotropic liquid crystalline structures based on polar lipids may be used as carriers and delivery 
system for different substances, due to their ability to solubilize and encapsulate both hydrophilic 
and hydrophobic compounds (98). Due to the three-dimensional nanostructures with hydrophilic or 
hydrophobic domains, liquid crystalline phases have been used for pharmaceutical DD applications: 
their large exchange surface area provide a complex diffusion pathway for conjugated compounds 
and their lipid constituents are biocompatible, bioadhesive and digestible (99). 
Depending on the surrounding environment and its molecular conditions, the amphiphilic 
components may self-assemble in different liquid crystalline phases: lamellar, reversed hexagonal 
or reversed bicontinuous cubic phase (100, 101). The bicontinuous cubic phase is composed by 
lipid bilayers arranged in periodic tridimensional structures turning into a shape with minimal 
surface (Fig. 1.10) (102). The interconnections of this structure transform this material into a 
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viscous gel (also called bulk gel) (103): this arrangement minimizes the molecular stress and free 
energy waste and produces bicontinuous lipid/water domains (104). 
The system may be in equilibrium with an excess of water that, in presence of a suitable surfactant 
agent, induces fragmentation of the bulk gel into a particulate dispersion of liquid crystalline 
nanoparticles (LCN) called cubosomes (105).  
 
 
Fig. 1.10. Scheme of cubosomes, showing the internal cubic structure and  membrane composition 
with different drug-loading modalities (redrawn by Bei et al., 2010). 
 
Although several methods have been tested for producing the cubic phase dispersion, no standard 
process is presently available to develop and control the properties and characteristics of such 
materials (106). In the past, cubosomes have been produced by combining polar lipids with water 
and feeding the system with heat energy. The resulting cubic liquid crystalline gel could be 
dispersed into particles by applying mechanical or ultrasonic energy. The energy input could be 
replaced by a hydrotrope, defined as a molecule with amphiphilic properties, but unable to display 
surfactant phase behaviour (i.e. micelle formation) (103). The hydrotrope can simplify the 
dispersion of liquid crystal particle formation (107): for example, ethanol can be used as a precursor 
able to spontaneously produce cubosomes when diluted (Fig. 1.11). The addition of the hydrotrope 
does not induce by itself cubosomes production, but increases the solubility of water-insoluble 
molecules such as polar lipids (103). The presence of stabilizer agents in solution, such as lecithin, 
polyethylene glycol or poloxamers, is known to help stabilization of the cubic phase dispersion, 
located on the surface of the cubosomes while preserving the inner structure of the particles (108, 
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109). In presence of an excess of water and mechanical stirring, the polar lipids swell and 
precipitate, forming a coarse dispersion, but preserving the inner cubic structure of the particles. 
Further reductions in size can be achieved by using ultrasonication or high pressure homogenization 
(110). The maintenance of the inner cubic structure is an important property for application since 
the lipid phase structure must maintain its integrity in the diluted media (106). 
 
 
Fig. 1.11. Ternary phase diagram for a glycerol monooleate (GMO)/ethanol/water system, whose 
lines indicate the water dilution values at which cubosomes are formed from an isotropic solution 
and an emulsion system (redrawn from: Malmsten, 2006).  
 
1.5.4 Glycerol monooleate 
 
Glycerol monooleate (Glyceryl oleate; (Z)-1-oleoyl-sn-glycerol; 1,2,3-propanetriol, 9-octadecenoic 
acid; monoolein) (GMO)/water system is one of the best known liquid crystalline systems for DD 
(111), due to its extensive polymorphism and widespread use in industrial products, e.g. food and 
cosmetics (Fig. 1.12). The GMO is a biocompatible and biodegradable polar lipid (99), which may 
swell in water, regardless of its very low water solubility (approximately 10
-6
 mol/l
-3
). This polar 
lipid may form a reversed bicontinuous cubic phase that in excess of water is thermodynamically 
stable (112) and exhibits mechanical stiffness (113). The cubic phase has a tridimensional periodic 
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conduit structure, composed by a network of surfactant bilayers and water channels, with a surface 
area of highly specific exchange. The properties of GMO-based cubic phases, among which an easy 
preparation process, biocompatibility, low cost of raw materials, temperature stability, bicontinuous 
structure, high internal surface area and solid-like viscosity, make them suitable for high rate 
production and pharmaceutical applications (103). 
 
 
Fig. 1.12. Structure of glycerol monooleate (retrieved from https://pubchem.ncbi.nlm.nih.gov 
/compound/5283468#section=Top). 
 
1.5.5 Drug delivery with liquid crystalline nanoparticles 
 
Polar peptides, proteins and drugs can be conjugated in a self-assembled lipid structure (liquid 
crystalline nanoparticle, LCN), becoming less vulnerable to chemical and proteolytic degradation 
(114, 115). Depending on its polarity and molecular structure in LCN, the conjugated compound 
will be located either in water or in the lipid domain of the system (116). The LCN structure may 
also be modified to include different types of drugs and control the kinetics of drug release (117). It 
has been shown that the addition of lipophilic compounds to GMO-based cubic LCN may induce a 
shift into a reverse hexagonal phase, while hydrophilic molecules can induce a transition to a 
lamellar liquid crystalline phase (111, 118). To date, LCN have been studied in vitro and in vivo on 
animal models for the delivery of numerous compounds: peptides (98), proteins such as insulin 
(119), ovalbumin (120), somatostatin (121), cyclosporin A (122), and drugs such as acetyl salicylic 
acid (aspirin) (123), lidocaine (124), sodium diclofenac (123), theophylline (125), timolol maleate 
(126) and vitamin E polyethylene glycol succinate (123). The results are encouraging because of 
sustained release in vitro (123-126) and in vivo (127) and increase of half-time life of the 
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conjugated compound (121). The rate of drug release in vitro is diffusion dependent (124, 128). The 
LCN have been tested in vivo through several delivery routes, including depot (129) and 
transdermal injections (130) and mucoadhesive applications(99).  
 
1.5.6 Liquid crystalline nanoparticles in the inner ear 
 
The LCN possessing a lipid core matrix with a surrounding shell of stabilizing agents have been 
tested in the inner ear. These NPs do not induce toxicological effects in vivo in mice after systemic 
applications (12 mg/kg intravenously for five days) (131) and their cell uptake and cell viability in 
vitro has been verified on fibroblasts by confocal scanner laser microscopy (132). In rat animal 
model LCN are able to cross the RWM and reach inner ear targets after middle ear application, 
without affecting hearing capacity (133). Their preferred pathway of diffusion inside cells has been 
investigated: LCN follow a “nerve pathway”, diffusing from the perilymph in the scala tympani to 
the spiral ganglion and nerve fibres, and later approaching inner and outer hair cells (134). The 
LCN diffusion variability and ability to cross the RWM depend on their lipid composition, size and 
external charge. The ability to cross the middle ear barrier has been shown to be size-dependent, 
because the percentage of particle diffusion is inversely proportional to their size (132). Surface 
charge may also affect uptake and biodistribution of LCN: after an in vivo application nearby RWM 
of LCN with different external charges, those expressing stronger positive charges were detected in 
the deeper turns of the cochlea. However, an increasing positive charge has been also related to a 
higher toxic effect in inner ear tissues (135). The LCN have also been tested as drug carriers, 
delivering dexamethasone in the inner ear through IT injection and comparing the results with a 
systemic application. The amount of dexamethasone detected in cochlear fluids after local LCN 
application is significantly higher compared to the systemic application, also increasing the drug 
half-life and average residence time in the perilymph by 1.9 folds (136). All these results indicate 
that LCN are suitable for sustained drug release and targeting of inner ear tissues after local 
administration. 
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1.5.7 Other nanoparticle-based drug delivery systems 
 
Several nanoparticle systems based on different materials and with different properties have been 
studied in vitro and in vivo with the aim of improving DD to the inner ear. A short description of 
physical-chemical characteristics of these NPs and their applications is reported below. 
Liposomes. They are artificial phospholipid bilayers, similar to those found in the cell membrane, 
but surrounding an aqueous core. They have a wide size range (between 50 nm and 5 µm) and 
morphology, depending on phospholipids used and on preparation method (137). Liposomes may 
encapsulate either hydrophobic molecules in the phospholipid bilayer or hydrophilic molecules in 
their aqueous core (138). The uptake of these NPs in vitro or in vivo usually relies on passive 
diffusion inside the cell, depending on their size (139, 140). 
Polymersomes. They are a wide class of amphiphilic copolymers, consisting of a self-assembled 
membrane of hydrophobic units, surrounding an aqueous core, and of a hydrophilic corona (141). 
Structurally similar to liposomes, their membrane thickness can be controlled by the molecular 
weight of the hydrophobic block of copolymers, achieving stronger, thicker and more stable 
membranes. The hydrophilic corona can be modified to regulate the biodistribution of 
polymersomes and to induce a specific cellular uptake (142). The hydrophilic drugs can be loaded 
in the core, while the hydrophobic ones in the membrane (143). Different multifunctional 
polymersomes have been studied for inner ear DD, including PEG-b-PCL (144), PHEA (145) and 
PLGA (90, 146-148). 
Silica NPs. They are modified colloidal silica particles (149) used for in vitro transfection of 
plasmid DNA (150), but also as a DD system. Applied near the RWM, these NPs were later found 
inside the inner hair cells, the vestibular hair cells, the spiral ganglion neurons and the supporting 
cells, without causing any hearing impairment (151).  
Supermagnetic iron oxide NPs. Magnetic NPs are synthetic Fe3O4 (magnetite) particles with a 
core diameter around 15 nm, that can be widely applied for magnetic targeting of cells(152). Unlike 
large ferromagnetic materials, the smaller supermagnetic iron oxide NPs (SPION) do not exhibit 
residual magnetic interactions when the magnetic field is not active, thus are more suitable for 
biomedical applications (153). The SPION, derivatized to increase biocompatibility and cell 
interactions, could be guided by an external magnetic field to a specific biological target, but they 
cannot encapsulate any drug (154). For in vivo applications, SPION were coated with organic 
compounds to prevent particle aggregation and facilitate dispersion (155). In inner ear DD, SPION 
 24 
 
have been encapsulated in PLGA (156), silica (154) and dextran (155) and their biocompatibility 
was tested and verified in vitro and in vivo (155). 
Hyperbranched poly-L-lysine (HBPL). They are highly cationic charged dendrimers widely used 
for non-viral gene transfer (67, 68). The HBPL were applied in vivo in Guinea pig inner ears 
without any sign of cell toxicity or permanent hearing loss: they were detected in the stria vascularis 
and hair cells (132). 
 
1.5.8 Key aspects for nanoparticle-based drug delivery in the inner ear 
 
Several parameters should be considered for nanoparticle-based local DD in the inner ear: the 
RWM permeability, the NPs cochlear targeting, their payload ability and controlled drug release, 
the biocompatibility and stability in cochlear fluids and tissues. All these aspects have been 
evaluated in vitro, ex-vivo or in vivo in animal models, but studies on their therapeutic efficacy are 
still in progress (1).  
The RWM is considered the main access to the inner ear after drug administration in the middle ear 
(157). The NPs with different composition and size between 10 nm and 640 nm are able to cross 
RWM. The size and the surface charge are key factors affecting NPs diffusion through RWM. The 
amount of NPs crossing from middle ear to inner ear is inversely proportional to the size of lipid 
NPs (139). In the cochlea the positively charged glycerol monooleate NPs achieve a larger 
distribution than neutral or negatively charged molecules (135). The process responsible for this 
passage was first described for lipid NPs as a paracellular pathway (134). Recent studies in the rat 
model suggest that the passage of liposome NPs may occur either by the paracellular pathway, or by 
endocytotic mechanisms based on clathrin and caveolin (144). 
In numerous studies NPs have been loaded or labelled with a fluorescent dye (rhodamine B, 
carboxycyanine, nile-red) or a contrast agent (gadolinium) for visualization of particles in cochlear 
cells or fluids by imaging techniques: nevertheless, the presence of NP was detected in inner ear 
tissues without a quantitative analysis. Liposome NPs have been detected in the cochlea until 6 days 
post-injection (157) and LCN until 7 days post-injection (134). The NPs surface has been also 
modified to improve DD target specificity: NPs functionalized by conjugation with nerve growth 
factor-derived peptides have shown specificity for spiral ganglion neurons and nerve fibres (158). 
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One of the major concerns in NPs clinical applications is biocompatibility. To date no hearing 
impairment, loss of hair cells or histological damages have been reported in studies with NPs (132, 
133, 159, 160), thus these systems appear reasonably safe. However, SPIONs tend to gather 
together when the magnetic field is removed, thus they form aggregates within the cell (144). The 
effects of LNC have been evaluated 20 days post-injection and no toxicity has been detected (157). 
Topic applications of liposomes in rats do not affect hearing, but a NP concentration-dependent 
toxicity has been observed in vitro in primary cochlear cell cultures (133). In most of these studies, 
a single intratympanic administration was employed: however, in order to improve liposome 
efficiency, a continuous NP release has been recently obtained through a high-performance 
polymide tubing equipped with a micro-pump; liposomes loaded with gadolinium-tetra-azacyclo-
dodecane-tetra-acetic acid have been visualized both in vitro by TEM and in vivo by MRI. In vitro 
intact NPs are free to diffuse in the medium, and in vivo are detected in the cochlea without adverse 
effects within six days (157). Again, no long-term effects of exposure to NPs after multiple 
applications in the inner ear have been detected up to date. 
The ability of NPs to carry drugs into the cochlea through the RWM is shown in vivo by several 
studies. Some SPION coated with PGLA and conjugated with dexamethasone enable the release of 
the drug in inner ear fluids, resulting in a higher concentration of dexamethasone in the perilymph 
compared to the pure drug diffusion (10% higher after 60 minutes, p<0.01) (161). The PLGA 
loaded with coumarin-6 enhance up to 10.9 times the local bioavailability of the dye in the 
perilymphin comparison to pure drug solution (147). Liposome loaded with the neurotoxic agent 
disulfiram induce a significant decrease of the number of spiral ganglion cells after two days from 
the administration (144). However, drug release by NPs has not yet been examined by long-term 
studies. 
The residence time of the drug within the middle ear cavity may be increased by NPs, but this does 
not guarantee direct contact between the loaded NP sand the RWM. The NPs also undergo the 
middle ear clearance through the Eustachian tube (162). A possible solution is to incorporate the 
NPs into a hydrogel, increasing their residence time in the middle ear and enhancing the drug 
release in the perilymph (26). The hydrogel applied near the RWM releases the loaded NPs in the 
perilymph along with its degradation. This approach has been recently reported: a poloxamer 407 
hydrogel combined with SPION was successfully applied on ex vivo models (in human temporal 
bones and explanted mouse inner ear cultures) (163); also a nanohydrogel based on chitosan 
polymer incorporating liposomes was tested in vitro and in vivo in the mouse model (73). The in 
vitro results show that NPs persisted without significant degradation for at least two weeks and 
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were released in a controlled and continuous way by the nanohydrogel. The in vivo results showed 
that NPs were successfully released by the nanohydrogel across the RWM and were able to reach 
the perilymph and the organ of Corti (164). 
Although NPs research in local DD for inner ear therapy appears promising, there are still many 
difficulties to overcome, mostly related to the inner ear anatomy, to the complexity of the cochlea 
and its highly differentiated cell populations, as well as the possibility to cause hearing loss using 
microsurgical approaches. The in vivo analyses of perilymph samples represent a technical 
challenge (97), because of the small volume of inner ear fluids in animal models (the total volume 
of perilymph in a Guinea pig amounts to about 10 µl) (165), and the possible contamination of 
samples by cerebrospinal fluid (97). The pharmacokinetics of drugs in the inner ear is therefore still 
unclear and there are no reliable quantitative data about local bioavailability, drug distribution and 
RWM permeability (1). Recently a computer pharmacokinetic software for inner ear fluids and drug 
distribution has been developed (166). The software outlines a model based on inner ear anatomy in 
humans and rodents, including the pharmacokinetic and the solute distribution parameters. This 
model has been used to simulate the distribution of therapeutic drugs and other compounds in the 
perilymph (95, 167). However, because of intraspecific variability of inner ear fluid volumes, and of 
RWM thickness and conditions, it is difficult to compare all current studies using different DD 
systems and draw quantitative conclusions about drug pharmacokinetics in the inner ear. 
 
1.6 Cell cultures as model for inner ear studies 
 
Numerous studies are involved in analysing the molecular mechanisms and the effects of drugs and 
new devices on the auditory system, with the aim to develop new therapeutic approaches. The in 
vivo studies nevertheless have to deal with key issues: the scarcity of the inner ear tissue, the 
variability of the response due to highly differentiated cell populations and the small size of the 
cochlea (168). To overcome these limits, cell cultures have been set up as in vitro models of inner 
ear cells. Two different cell lines were employed in this study to test toxic and protective effects of 
various compounds: an Organ of Corti cell line (OC-k3) and a cell line derived from rat 
pheochromocytoma (PC12). 
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1.6.1 The OC-k3 cell line 
 
The OC-k3 cells were isolated in 1999 and derive from the inner ear of an immortalized mice. 
When cultivated in permissive conditions (33 °C and medium culture enriched with interferon-γ) 
these cells exhibit a fusiform aspect and a highly replicative capacity: they can be replated up to 50 
times without losing their characteristics (169). The OC-k3 express an inner ear unique protein, 
called Organ of Corti Protein 2. This cell line shows specific epithelial characteristics: they are 
positive for nestin, a marker of epithelial precursors; they express markers typical of the auditory 
sensory cells (such as myosin VII and acetylcholine α-9 receptor) and of the supporting cells (such 
as connexin 26), but not the markers of neurons or glia cells. They are therefore considered a good 
in vitro model to study hair cells of the inner ear and have already been used for studies on 
ototoxicity induced by drugs such as gentamicin and cisplatin (170-173).  
 
1.6.2 The PC12 cell line 
 
The PC12 cells were isolated in 1976 from rat pheochromocytoma, a tumour of the chromaffin cells 
of the adrenal gland (174). When cultivated in permissive conditions they have a rounded shape and 
they can be reseed up to 70 times without losing their characteristics. The PC12 cells can 
differentiate into neural-like cells when treated with 50 ng/ml of nerve growth factor for 7 days: 
they lose their replicative capacity and start growing typical neural cell processes, known as 
neurites. The PC12 cells can synthesize neurotransmitters such as norepinephrine and dopamine, 
possess type N and T calcium channel (175) and may release calcium-dependent exocytotic vesicles 
(174). For all the above characteristics they are considered a good model for study of neural cells. 
Only a few studies have been performed on the effects of oxidants (176) and cisplatin (177) on 
undifferentiated PC12 cells, and others have dealt with the effects of cisplatin on differentiated 
PC12 (178). 
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2 Aim of the work 
 
The aim of this thesis is to develop a new nanoparticle-based system conjugated with two 
hydrophobic drugs, coenzyme Q10 and dexamethasone, and test it in vitro on PC12 and OC-k3 
cells, used as a model of inner ear cell populations, to evaluate the protective effects against 
cisplatin cytotoxicity. 
Nanoparticles (NPs) represent an innovative approach for inner ear treatments; when applied nearby 
the round window, NPs are known to be detected in all parts of the cochlea, improving the 
distribution and the half-life of the conjugated compound. Liquid crystalline NPs based on glycerol 
monooleate are a promising NPs system that can internalize hydrophobic drugs in their lipid matrix. 
The aim of this work is to produce NPs highly biocompatible that can be conjugated to improve the 
delivery of hydrophobic drugs compared to the treatment with the drug alone, achieving better 
results while reducing the amount of drug used.  
Among drugs tested against noise or drug induced ototoxicity there are antioxidants and 
glucocorticoids. Antioxidants, such as coenzyme Q10, are known to reduce the formation of 
reactive oxygen species (ROS) in the cochlea when applied as a pre-treatment, but have a very low 
solubility and bioavailability. Steroid drugs, such as dexamethasone, are currently used for inner ear 
therapies but, besides their low solubility, their high dosage may induce numerous side effects. 
Local application of drugs within the inner ear also relies only on passive diffusion, which requires 
high amounts of drugs. It is therefore necessary to develop a system for a controlled and sustained 
delivery of drugs within the cochlea. 
Cisplatin is a widely used antitumor agent: it is highly cytotoxic and its use leads to numerous side 
effects, including ototoxicity through the formation of ROS, inflammation and DNA damages to the 
inner ear tissues. The development of a specific NPs system for local treatment of the inner ear 
could prevent the occurrence of ototoxicity and hearing loss, without affecting the anticancer effects 
of cisplatin applied systemically. 
The studies performed for this thesis represent a preclinical work on the effects of NPs in vitro on 
PC12 and OC-k3 cell lines and on the protective effects of NPs conjugated with two compounds 
(coenzyme Q and dexamethasone) against cisplatin cytotoxicity. 
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3 Materials and methods 
 
3.1 Nanoparticles production and physical-chemical characterization 
 
3.1.1 Reagents 
 
Glycerol monooleate (GMO RYLO MG 19 Pharma) was purchased from from Danisco A/S 
(Grindsted, Denmark). The composition of the sample according to the manufacturer was minimum 
95% monoglycerides, maximum 10% diglycerides and maximum 2% triglycerides. The fatty acid 
content was minimum 88 % oleoyl (C18:1). The triblock copolymer poly(ethylene oxide)(PEO)-
poly(propylene oxide)(PPO)-poly(ethylene oxide)(PEO) (trade name Lutrol F127) was obtained 
from BASF (Lundwigshafen, Germany) and its approximate formula is PEO101PPO56PEO101 and 
have an average molecular weight of 12600 g/mol.  
Coenzyme Q10 (C9538, powder, purity ≥ 98% for HPLC, formula weight 834.34 g/mol) and 
dexamethasone (9α-fluoro-16α-methylprednisolone, D1756, powder, purity ≥ 98% for HPLC, 
molecular weight 392.46) were purchased from Sigma-Aldrich (St Louis, Missouri, U.S.A.). 
 
3.1.2 Preparation of liquid crystalline nanoparticles 
 
Nanoparticles (NPs) were prepared by dilution of an isotropic mixture of 5% wt lipid and 5% wt 
ethanol in F-127 1% solution. Incorporation of CoQ10 and dexamethasone was performed 
dissolving the active compounds in the lipid blend. The coarse samples were then homogenized five 
times for 5 minutes through a microfluidizer (MF) (Microfluidizer M-110s, Microfluidics Corp., 
Newton, USA) equipped with a Z-type interaction chamber with a minimum passage of 100 μm. 
The fine liquid crystalline nanoparticle dispersions were heated in a steam sterilization autoclave 
Laboklav 25 (SHP Steriltechnik AG, Detzel Schloss/Satuelle, Germany) at 121 °C for 20 min. The 
total time for sterilization and cooling was about 1 hour. Samples were then stored at 4 °C.  
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3.1.3 Dry content and concentration of active compound 
 
The dry content of the LCNP dispersions was analysed by freeze-drying a pre-weighed sample 
using a Epsilon 2-4 LSCplus freeze drier (Martin Christ Gefriertrocknungsanlagen GmbH, Osterode 
am Harz, Germany). The concentrations of active compounds in the LCNPs were assessed by 
diluting the freeze-dried particles in ethanol followed by analysis by UV spectrometry (Lambda 
650, PerkinElmer instruments LLC, Shelton, USA) at 274 nm for CoQ10 and at 278 nm for 
dexamethasone. 
 
3.1.4 Particle size 
 
The size of the NPs was detected by a Zetasizer Zen3600 measurer (Malvern Instruments Ltd., 
Worcestershire, U.K.) using disposable cuvettes. The samples were diluted 10 times in purified 
water prior to analysis in disposable cuvettes, and measured 3 times: each measurement consisted of 
12 sub-runs. Refractive indices were set to 1.47 and 1.33, for lipids and water, respectively, and the 
temperature were kept at 25 °C during measurements. Data presented in this study correspond to the 
zeta-average particle size. 
 
3.1.5 Zeta potential 
 
The zeta potential of particles with and without drug loaded was determined by measuring the 
electrophoretic mobility with the Zetasizer Zen3600 (Malvern Instruments). Samples were diluted 
in purified water or 5 mM acetate buffer (pH 5.5) to a particle concentration of 0.5-2.0 mg/ml, and 
analysed in disposable measuring cells at 25 °C. Each sample was measured in triplicate. 
 
3.1.6 Cryogenic Transmission Electron Microscopy (CRYO-TEM) 
 
The samples were prepared in a vitrification system with controlled environment, kept at 25 °C and 
with humidity close to saturation to prevent evaporation from the sample during preparation. A 
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droplet of each dispersion was placed onto a carbon-coated “holey” polymer film supported by a 
copper grid, gently blotted with a filter paper to from a thin liquid film (10-500 nm) and plunged 
into liquid ethane at -180 °C. The sample was then transferred into liquid nitrogen at -196 °C into a 
Zeiss LIBRA-120 transmission electron microscope (Carl Zeiss, Oberkochen, Germany) operating 
at 80kV and with a working temperature below –160 °C to prevent formation of ice crystals. 
 
3.2 In vitro analyses 
 
3.2.1 Cell cultures 
 
The OC-k3 cells were cultured at 37 °C and 10% CO2 with complete culture medium DMEM 
(Dulbecco Modified Eagle’s Medium; Gibco BRL, Gaithersburg, Maryland, U.S.A.), 10% FBS 
(Fetal Bovine Serum; Gibco BRL), L-glutammine 2 mM (Gibco BRL), 50 U/ml Interferon γ (IFN, 
Genzyme, Cambridge, Massachusetts, U.S.A.), 1% penicillin – streptomycin (Gibco BRL). 
The PC12 cells were cultured at 37 °C and 5% of CO2 with complete culture medium RPMI 1640 
(Roswell Park Memorial Institute Medium, Gibco BRL), 10% HS (Horse Serum, Gibco BRL), 5% 
FBS (Fetal Bovine Serum, Gibco BRL), L-glutammine 2mM (Gibco BRL), 1% penicillin – 
streptomycin (Gibco BRL).  
 
3.2.2 Treatments and co-treatments 
 
For all the treatments and for the co-treatments including the NPs and the cisplatin (CDDP, 1 mg/ml 
- Accord Healthcare, Milan, Italy), performed on both PC12 and OC-k3 cell lines several 
concentrations of the different compounds have been tested (Table 1). For every different condition, 
all the following test were performed, for the times indicated for each of the methods. 
When performing co-treatments analyses, CDDP was added to cells 24 hours after the treatment 
with NPsD and NPsQ. The culture medium was replaced in order to avoid interferences between 
CDDP and NPs. The protection rate was detected after 24/48 hours from the CDDP treatment. The 
control samples were treated only with CDDP, NPsD or NPsQ.  
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Table 1. Concentrations of nanoparticles (NPs) (µg/ml) and cisplatin (CDDP) (µM) tested on OC-
k3 and PC12 cell lines. *= concentrations used in the protection analyses. NPsA: non-conjugated 
nanoparticles. NPsQ: NPs conjugated with coenzyme Q. NPsD: nanoparticles conjugated with 
dexamethasone. 
Treatment NP concentrations (µg/ml) tested 
in OC-k3 
NP concentrations (µg/ml) tested    
in PC12 
NPsA 10-25-50-75-100-125-150  10-25-50-75-100-125-150-200 
NPsQ 10*-25*-50*-75-100-125-150 10-25*-50*-75*-100*-125-150-200 
NPsD 10*-25*-50*-75-100-125-150 10-25-50-75-100-125-150-200 
NPs + rodhamine B 25-50 50-100 
CDDP 2.5-5*-13*-25-50  2.5-5*-13-25-50 
   
 
3.2.3 Viability assays 
 
Cell were spread on a 96-wells plate adding 5000 cells in 100 µl of medium per well. After 24 
hours, cells were treated with different concentration of NPs or CDDP. Each concentration was 
tested in threefold and every experiment was repeated three times against suitable controls. Cells 
were tested by adding 20 µl of a tetrazolium compound [3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4- sulfophenyl)-2H-tetrazolium, inner salt; MTS] (CellTiter 96® 
AQueous MTS Reagent Powder, Promega, Woods Hollow Road, Madison, Wisconsin, U.S.A.) and 
an electron coupling reagent (phenazine methosulfate, PMS) (Sigma Aldrich) at rate 20:1. After 3 
hours of incubation at 37 °C the plate was read at 492 nm, using a SIRIO plate reader (SEAC s.r.l, 
Florence, Italy). The absorbance value obtained for each sample, expressed as optical density (OD), 
was normalized to the mean value of the respective non-treated sample, considered as 100% 
viability rate.  
 
3.2.4 Cell cycle analyses 
 
For analyses of the cell cycle, about 150000 cells were spread into six-well plates in 2 ml of 
medium. After treatments, cells were collected into a sterile test tube, centrifuged at 1500 rpm for 5 
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min and the resulting pellet was washed with PBS 1X while the supernatant was discarded. The 
pellet was fixed in 70% ethanol, added dropwise while stirring. In these conditions samples could 
be stored for one month at -20 °C. Before performing flow cytofluorimetry analyses, the samples 
were centrifuged and washed twice with PBS 1X. The pellet was resuspended in a solution of PBS 
1X, RNase 100 µg/ml and PI 50 µg/ml, and left at room temperature for 1 hour. Samples were 
analysed in a BD FACSCalibur cytofluorimeter (BD Biosciences, San José, California, U.S.A.) to 
study the cell cycle. The Standard Optical Filter 585/42 nm (FL2) channel was used to discriminate 
the percentage of cells in each phase of the cell cycle and the values obtained were indicated as an 
area (FL2-A) in the results. 
 
3.2.5 Morphological analyses  
 
For both OC-k3 and PC12 cell lines, about 150000 cells per well were seeded and spreaded on a 
glass slide, with pre-addition of collagen layer for PC12 cells. Treated cells were stained with 
annexin V-fluorescein isothiocyanate (FITC) and propidium iodide (PI) kit (Abcam, Cambridge, 
U.K.) to evaluate the presence of apoptosis. To evaluate the state of cytoskeleton and nucleus, cells 
were fixed in Glyo –fixx (Thermo Scientific ) for 30 min at room temperature, then permeabilized 
and stained with phalloidin – tetramethylrhodamine (TRITC) 1 µg/ml (Sigma Aldrich) for 2 hours 
at room temperature. After being washed in PBS 1X, cells were stained with 4’,6-diamidino-2-
phenylindole (DAPI) 1 µM (Sigma Aldrich) for 5 min in the dark. The slides were then mounted on 
a microscope slide with glycerol 20% for observation at the fluorescence microscope. For 
internalization tests, NPs were administered to cells attached to the slides and then observed at the 
optical fluorescence microscope after 1-2-4-8-24-48 hours. The optical fluorescence microscope 
used was a Nikon Eclipse TE2000-U model (Nikon, Milan, Italy) and the images were acquired 
using the programme Nis-Elements 3.0 Image Analysis System software (Nikon). 
 
3.2.6 Real time quantitative polymerase chain reaction 
 
For Real time quantitative polymerase chain reaction (RTqPCR), total RNA was isolated from 
cultured OC-k3 and PC12 cells using innuPREP Micro RNA Kit (Life Science, Jena, Germany). 
Total RNA extracted was processed with DNAase I (RNase-free) M0303S kit (New England 
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Biolabs, Ipswich, USA). Retrotranscription was performed using Euroscript M-MLV Reverse 
Transcriptase kit (Euroclone, Milan, Italy): 0.5 µg RNA, 0.5 µg oligo (dT), 0.2 µg random 
hexamers and H2O up to 12.5 µl were incubated at 65 °C for 5 min. Afterwards, 4 µl of reaction 
buffer, 0.5 µl RNase inhibitor (20 units), 2 µl of dNTP (10 mM) and 1 µl Euroscript Reverse 
Transcriptase (200 units) were added to the solution. The final mix was incubated at 60 min at 42°, 
then 10 min at 70°. The primers (forward, F, and reverse, R) were designed using the PerlPrimer 
software 1.1.21 (Sourceforge; http://perlprimer.sourceforge.net/). RTqPCR was performed with 
Chromo4
TM
 system (BioRad, Milan, Italy) adding 5 µl of SSoFast
TM
 EvaGreen® Supermix, 100 ng 
cDNA, 1 µl primer forward + primer reverse mix in ratio 1:1 (final concentration 300 nm) and H2O 
up to 10 µl, using Opticon Monitor
TM
 3 software (BioRad). Every reaction ran for 31 amplification 
cycles for a total time of 80 minutes; the reaction temperature depended on the used primers 
specification. Every analysed condition was repeated in threefold. RTqPCR data of interest genes 
are analysed with comparative CT methods using GenEx 6.1 software (bioMCC, 
http://www.biomcc.com/genex-software.html) taking as reference at least three housekeeping 
genes. The primer used are listed in Table 2. 
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Table 2. Primers used for RTqPCR analyses. 
Primer  Sequence  
Species  
(F + R) 
Annealing 
temperature 
(°C) 
ACTB forward 
ACTB reverse 
CGTTGACATCCGTAAAGACC 
TAACAGTCCGCCTAGAAGCA 
Mouse 60 
Caspase 3 forward 
Caspase 3 reverse 
GTTACTATTCCTGGAGAAATTC 
GACACAATACACGGGATCTGT 
Mouse/rat 60 
Caspase 8 forward 
Caspase 8 reverse 
CGGACTTCAGACAAAGTTTACCA 
ACTCAGAGCCTCTTTATCACAG 
Mouse/rat 60 
Caspase 9 forward 
Caspase 9 reverse 
GCAGATATGGCATACACCCT 
GGATGACCACCACAAAGCAG 
Mouse/rat 60 
BAX forward 
BAX reverse 
CTAGCAAACTGGTGCTCAAGG 
CTCAGCCCATCTTCTTCCAG 
Mouse/rat 60 
p53 forward 
p53 reverse 
CTCCTCCCCAGCATCTTATCCG 
CTGTCCCGTCCCAGAAGGTTC 
Mouse 60 
Bid forward 
Bid reverse 
ACTTGGTTAGAAACGAGATGGAC 
GGCGTAAACTCTTCAGATACACTC   
Mouse 58.4 
β2 microglobulin forward 
β2 microglobulin reverse 
CGAGACCGATGTATATGCTTGC 
GTCCAGATGATTCAGAGCTCCA 
Mouse/rat 60 
ACTB forward 
ACTB reverse 
CGTTGACATCCGTAAAGACC  
GATAGAGCCACCAATCCACAC 
Rat 60 
Caspase 3 forward 
Caspase 3 reverse 
GAACCAGATCAGAAGCTCCT  
CTTTCCAAGTCCCGTGTG 
Rat 57.4 
Caspase 8 forward 
Caspase 8 reverse 
CCAAATGAAGAGCAAACCTCG  
GATACTAGAACCTCATGGATTTGAC 
Rat 60 
Caspase 9 forward 
Caspase 9 reverse 
TTTCTTAGCAGTCAGGTCGT 
GCCACCTCAAAGCCATGGT 
Rat +  
Mouse/rat 
59 
p53 forward 
p53 reverse 
TTTGAGGTTCGTGTTTGTGC  
TTTTATGGCGGGACGTAGAC 
Rat 61 
Thrombomodulin forward 
Thrombomodulin  reverse 
GCTCTGTACCTCTCCTTTCTC 
TTCAAGTCCTCCCTACCCTC 
Mouse/rat 60 
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3.2.7 Western blot 
 
A SDS-PAGE gel was used to evaluate the expression of proteins extracted from cells. The total 
protein concentration was determined using the Pierce
TM
 BCA Protein Assay Kit (Thermo 
Scientific, Waltham, Massachusetts, U.S.A.). The acrylamide percentage varied from 10 to 20 % 
depending on the analysed proteins. Gel electrophoresis ran with an intensity between 30 and 80 
mA; proteins were then transferred to a 0.2 or 0.45 µm polyvinylidene difluoride (PVDF) blotting 
membrane (GE Healthcare, Amersham, Buckinghamshire, U.K.) by Semi-dry transfer system 
(Celbio S.p.a., Milan, Italy). To verify if the transfer is successful blots were stained with Ponceau 
Red or Pierce® Reversible Protein Stain Kit (Thermo Scientific), while the SDS-PAGE gel was 
stained with Coomassie blue to detect residual proteins. 
Primary antibodies were dissolved in 5 % (w/v) milk in TBST buffer (10 mM Tris-HCl, pH 7.4, 
137 mM NaCl, 0.1% (v/v) Tween-20) or in 3 % (w/v) BSA in PBST buffer (PBS 1X, 0.1% (v/v) 
Tween-20). Each final concentration followed the manufacturer’s instructions (Table 3). Blots were 
exposed to primary antibody for 2 hours at room temperature or overnight at 4 °C. Secondary 
antibodies were dissolved in 5% milk (w/v) (Table 4). Blots were exposed to secondary antibody 
for 1 hour at room temperature.  
 
Table 3. Primary antibodies used for Western Blot. All antibodies were obtained from Santa Cruz 
Biotechnology (Dallas, Texas, U.S.A.). 
Antibody Produced in Molecular weight Dilution Commercial/catalog n° 
Caspase 3  Rabbit 32 - 17 1:250 sc-7148 
ERK-1 Rabbit 42 - 44 1:500 sc-94 
pERK Mouse 42 - 44 1:500 sc-154 
HSP 70 Goat 70 1:500 sc-1060 
PARP 1/2 Rabbit 116 1:500 sc-7150 
β-actin Mouse  43 1:500 sc-47778 
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Table 4. Secondary antibodies used for Western Blot. 
Antibody Species Dilution Company and catalog n° 
Anti goat IgG  rabbit 1:1000 Santa Cruz Biotechnology sc-2768 
Anti rabbit peroxidase IgG  goat 1:1000 Sigma Aldrich A4416 
Anti mouse peroxidase IgG  goat 1:1000 Sigma Aldrich A6154 
 
3.2.8 Ultra performance liquid chromatography (UPLC) 
 
The drug loading efficiency in NPs was quantified by separating the NPs from the suspension liquid 
by centrifugation at 15000g for 30 min through Amicon Ultra-0.5 filter devices (Ultracel-100 K, 
Merck Millipore Ltd., Cork, Ireland). To analyze the release of dexamethasone from NPsD in OC-
k3, cells were spread as a monolayer on a Petri dish and treated with NPsD 50 µg/ml for 4, 24 and 
48 hours. After each exposure time, the cell medium was collected while cells were harvested and 
treated with lysis buffer (NaCl 300 mM, EDTA 5 mM, Triton X-100 0.5%, H2O), centrifuged at 
15000g for 20 min. Finally, the supernatant and the cell pellet (dispersed in H2O) were collected 
separately. Cell medium, lysate and pellet samples were prepared for UPLC analysis diluting 100 µl 
each sample with 100 µl dichloromethane (DCM), then centrifuging at 14000g for 4 min at 4 °C 
and collecting 100 µl of the separate phase on the bottom of the vial. The drug concentration in the 
filtrate was quantified using an UPLC system (Waters Corp., Milford, Massachusetts, USA) with an 
ultraviolet (UV).  The system was equipped with a C18 column (1.7 µm, 2.1 mm X 150 mm; Model 
Acquity BEH300, Waters Corp.) operating at 40 °C. The mobile phase was acetonitrile/water 1:9 
plus 0.03% of trifluroacetic acid (phase A) and acetonitrile/water 1:9 plus 0.03% of trifluroacetic 
acid (è uguale??) (Phase B) at a flow rate of 500 µl/min. A gradient was used where the mobile 
phase composition was changed from 100% phase A to 39% (phase B) over a period of 3.4 min. 
The injection volume is 10 µl and the absorbance was measured at 292 nm (dexamethasone). The 
concentration of the drug in the filtrate was determined using a calibration curve and a correction 
factor compensating for adsorption to the filter. The amount of drug conjugated to the NPs could 
then be calculated as ng/ml. 
  
 38 
 
3.2.9 Statistical analyses 
 
Data were analysed by the program GraphPad Prism 7 (GraphPad Software, Inc., La Jolla, 
California, U.S.A.) to perform t-test and one-way ANOVA tests to identify significant results. 
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4 Results 
 
Nanoparticles (NPs) were characterized in this study according to their physical chemical properties 
and their interactions with cells. In detail, the effects of treatment with NPs were studied in two cell 
lines used as model for inner ear tissues, examining the toxicity, the cell uptake, the cell 
morphological variations, the activation of molecular pathways and the expression of genes related 
to cell stress. All analyses were also performed on NPs conjugated with anti-inflammatory and 
antioxidant compounds, with the aim to develop ways of prevention of cisplatin ototoxicity. 
 
4.1 Physical chemical characterization of NPs 
 
The NPs produced as previously described in the Materials and Methods section were analysed for 
their physical chemical properties and stability in time; moreover, their morphology was examined 
by cryogenic transmission electron microscopy (CRYO-TEM). For each NPs batch produced, 
viability tests were performed in vitro on two cell lines, the rat pheochromocytoma PC12 line and 
the organ of Corti OC-k3 line, in order to evaluate the effects of NPs on inner ear cell models. 
Four types of NPs were produced for this study: a control NP without any conjugated drug called 
NPsA; a NP conjugated with coenzyme Q10 (2,3-dimethoxy-5-methyl-6-decaprenyl-1,4 
benzoquinone, CoQ10) called NPsQ; a NP conjugated with dexamethasone called NPsD; a NP 
conjugated with the fluorescent dye rhodamine B. The NPs size ranged from 150 and 250 nm 
(Table 5) and were highly homogeneous, with a low polydispersity index (PDI). All NPs have a 
slightly negative surface charge (Table 5), due to the properties of the lipid used for particle 
synthesis, the glycerol monoleate (GMO). A slight surface charge is required for nanomaterial 
cohesion and guarantees its stability over time, preventing autoaggregation of NPs.  
The physical chemical parameters of all NPs, that is size in nm, PDI, electrokinetic potential in 
colloidal dispersions (Z potential, mV), active concentration expressed as percentage of total dry 
weight over percentage of total weight in formulation, are indicated in Table 5. The differences 
among the physical chemical parameters are probably due to the conjugation of NPs with the drug, 
involving steric bulks and variations of the surface charge. The stability of physical chemical NPs 
stored a 4°C (except NPs plus rhodamine B) was verified at day 0. day 30 and day 60 after 
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preparation: the data are shown respectively in Table 6 and Table 7. No significant variations were 
detected in physical chemical parameters up to 60 days after preparation. 
Table 5. Physical chemical parameters of the nanoparticles studied. Active concentration is 
expressed as percentage of total dry weight over percentage pf total weight in formulation. SD, 
standard deviation. 
Nanoparticle 
Size 
(nm ± SD) 
PDI                     Z potential (mV) 
NPsA 190.7 ± 1.1 0.026 -21.4 
NPs + rhodamine B 250.1 ± 1.1 0.150 -15.0 
 
Table 6. Variations of size and polydispersity index (PDI) of NPs stored at 4°C, measured at 
different time intervals. 
Nanoparticle 
Day 0 
Size (nm ± SD), PDI 
Day 30 
Size (nm ± 0.1), PDI 
Day 60 
Size (nm ± 0.1),  PDI 
NPsA 212 ± 1.1 0.026 211 ± 0.9 0.050 246 ± 1.4 0.064 
NPsQ 177 ± 1.2 0.179 142 ± 1.3 0.173 158 ± 0.9 0.14 
NPsD 262 ± 1.9 0.036 227 ± 1.2 0.042 226 ± 1.4 0.026 
 
Table 7.Variations of the surface charge of NPs, stored at 4 °C, measured as electrokinetic potential 
in colloidal dispersions (Z potential) at the same time intervals as in Table 6. 
 
Nanoparticle 
 
 
Day 0 
 
 
Day 30 
 
 
Day 60 
 
NPsA -21.4 -14.7 -18.8 
NPsQ -22.9 -26.9 -22.5 
NPsD -20.4 -17.3 -20.5 
 
The physical chemical analyses by cryogenic transmission electron microscopy (CRYO-TEM) 
allowed to visualize the structure of NPs produced and to evaluate in detail their size and variations. 
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The NPsA showed a cubic structure (“cubosome”) and size about 200 nm, but several lamellar 
structures were interspersed among the cubic particles (Fig. 4.1A, B). 
The NPsQ and NPsD analysed by CRYO-TEM exhibited a different morphology: they had a rather 
roundish (Fig. 4.2A, B) or hexagonal (“hexosome”) (Fig. 4.3A, B). The conjugation of NPs with the 
drug induced therefore a change in the morphology of NPs. 
 
 
Fig. 4.1. Structure of NPsA by CRYO-TEM. A. Image at low magnification. B. Detail of a NPsA. 
Scale bars as indicated. 
 
Fig. 4.2. Structure of NPsQ by CRYO-TEM. A. Image at low magnification. B. Detail of a NPsQ. 
Scale bars as indicated. 
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Fig. 4.3.. Structure of NPsD by CRYO-TEM. A. Image at low magnification. B. Detail of a NPsD. 
Scale bars as indicated. 
 
4.2 Characterization of NPs in vitro 
 
The in vitro toxicity of NPs was evaluated on cell lines by a tetrazolium reduction assay (MTS), as 
described in the Materials and Methods section. This test allows to identify the best dosage of NPs 
with no toxic effects for morphological and molecular experiments, and allows also to verify the 
reproducibility of results and the standardization of NPs preparation processes. 
 
4.2.1 Characterization of NPsA 
 
For PC12 cell line, the percentage of viability significantly increased when the cells were treated 
with NPsA up to 100 µg/ml for 24 hours and up to 150 µg/ml for 48 hours (Fig. 4.4). At 24 hours, 
the difference in comparison to untreated controls (0 µg/ml NPsA, 100% viability) was significant 
from 75 µg/ml (p<0.05) to 100 µg/ml (p<0.001). At 48 hours, the difference in comparison to 
untreated controls was significant from 25 µg/ml (p<0.05) to 125 µg/ml (p<0.001). Viability was 
different between the two exposure times after 24 hours of treatment compared to the 48 hours at 
NPsA concentration 175 µg/ml (p<0.05), while it was higher after 48 hours of treatment compared 
to the 24 hours values at NPsA concentrations 75 µg/ml and 125 µg/ml (p<0.05). From 100 µg/ml 
on, the cell viability decreased and a slight toxicity was detected. The effect of NPsA on PC12 may 
therefore be described as dose and time dependent. Based on the above data, the concentration 
range chosen for all analyses conducted on NPsA was 50 - 100 µg/ml. 
A 
 43 
 
 
Fig. 4.4. In vitro toxicity of NPsA on PC12 cells, expressed as percentage of cell viability vs. NPsA 
concentration. Bars represent the standard errors. Asterisks indicate significant differences in 
comparison to untreated controls and dots represent significant differences between exposure times. 
* = p<0.05; ** = p<0.01; ***= p<0.001; • = p< 0.05. 
 
In order to verify whether the variations in cell viability could be associated to alterations of the cell 
cycle, PC12 cells treated with NPsA up to 100 µg/ml were analysed by flow cytofluorimetry after 
24 and 48 hours of treatment. The results did not show any significant variation of cell distribution 
in the cell cycle phases in comparison to controls (Fig. 5A, B). No increase in hypodiploid cell 
population (thus with fragmented nuclear DNA because of the onset of apoptosis) was detected at 
the concentrations tested. No significant differences were also observed between the two exposure 
times (Fig. 5C, D). 
The absence of cell cycle alterations after treatment with NPsA, together with the results of cell 
viability tests (Fig. 4.4), suggests that concentrations of NPsA up to 100 µg/ml do not cause 
significant damage to cells, because they maintain a normal ability to reproduce and show a higher 
viability after 48 hours of treatment in comparison to 24 hours. 
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Fig. 4.5. Analyses by flow cytometry of PC12 cells treated with NPsA at 50, 75 and 100 µg/ml for 
24 and 48 hours. A, B. Number of cells (expressed as counts) in each phase of the cell cycle. For 
each experimental condition, about 20000 events were analysed. NT, untreated control. APOP, 
apoptosis. C, D. Distribution of cells expressed as percentage of gated cells± standard error in each 
cell cycle phase. 
 
The next analysis conducted on PC12 treated with NPsA was the morphological one. When cells 
were observed by phase contrast optical microscopy, small vesicles could be detected inside the 
cells in the perinuclear region (Fig. 4.6A). At increasing concentrations of NPsA, the number of 
vesicles increased. At very high concentrations (200 µg/ml, thus toxic according to the cell viability 
tests) large vesicles were visible inside the cells, which appeared swollen and deformed. This dose 
dependent effect is apparently due to the uptake of NPsA inside the cell (although it is unclear 
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whether these vesicles actually contain the internalized NPs) and to the consequent increased 
osmotic stress. 
 
Fig.4.6. Phase contrast images of PC12 cells treated with NPsA. Magnification 40x. A. 75µg/ml: 
arrow heads indicate small perinuclear vesicles. B. 200µg/ml: arrows indicate large vesicles. 
 
To verify the uptake of NPs within the cell, analyses by fluorescence microscopy were therefore 
performed by treating PC12 cells with concentrations of 50 µg/ml and 100 µg/ml of NPs conjugated 
with the fluorescent dye rhodamine B (9- (2- carboxyphenyl)- 6- diethylamino- 3-xanthenylidene]- 
diethylammonium chloride). The cells were monitored up to 48 hours (Fig. 4.7). 
In the first four hours of treatment no signal was detected, but from 8 hours on an intense 
fluorescent signal was detected inside the cells, showing that NPs were internalized. The signals 
inside the cells remained dot-shaped and localized in the perinuclear region. A detailed comparison 
with the phase contrast images showed that the signal was not restricted to the vesicles observed in 
the previous stage. Although a quantitative analysis was not performed, the signals resulted intense 
and stable at 24 hours of treatment, indicating that most NPs were internalized within that time 
interval. At 48 hours the signals clearly decreased. 
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Fig. 4.7. Fluorescent microscope images and colour-combined (phase contrast plus fluorescence) 
images of PC12 cells treated with 50 and 100 µg/ml NPs conjugated with rhodamine B up to 48 
hours. Magnification 40x. 
 
The morphological observations of treated cells was integrated by analyses with fluorescent cell 
markers: annexin V conjugated to the green dye fluorescein isothiocyanate (annexin V-FITC) and 
propidium iodide (PI), respectively markers of the initial and late apoptotic phases; 4’,6-diamidino-
2-phenylindole (DAPI) and phalloidin-tetramethyl rhodamine B isothiocyanate (phalloidin-TRITC), 
respectively markers of cell nuclei and cytoskeleton. 
When PC12 cells were treated with NPsA up to100 µg/ml, and marked with annexin V-FITC and 
PI, no double green-red fluorescent signal was observed, therefore no apoptosis occurred in these 
cells (Fig. 4.8). The staining by DAPI did not show any variation in nuclei (Fig. 4.9, blue stain) and 
no alterations were detected in the cytoskeleton marked by phalloidin-TRITC (Fig. 4.9, red stain). 
Although the cytoskeleton was not completely visible because of the roundish and flattened shape 
of PC12 cells, the conservation of their shape after treatment with NPsA represented a good 
indicator of the cytoskeleton normal condition. 
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Fig.4.8. Morphological investigations with the fluorescent markers annexin V-FITC (green) and 
propidium iodide (PI) (red) on PC12 cells treated with NPsA 100 µg/ml at 24 and 48 hours. Images 
a, c, e, g are phase contrast. NT, untreated control. White arrows indicate cells in apoptosis or 
necrosis. Magnification 40x. 
 
Fig. 4.9. Morphological investigations with 4’,6- diamidino- 2-phenylindole (DAPI) (blue) and 
phalloidin-tetramethyl rhodamine B isothiocyanate (phalloidin-TRITC) (red) on PC12 cells treated 
with NPsA 100 µg/ml at 24 and 48 hours. Images a, c, e, g are colour-combined DAPI-phase 
contrast. NT, untreated control. Magnification 40x. 
 
The analysis of gene expression profiles by real time quantitative PCR (RTqPCR) concerned some 
genes related to the apoptotic process, with the aim to connect all results and identify the signal 
pathways activated in the cell after NPs treatments. Both pathways of apoptosis, the extrinsic and 
the intrinsic one, were examined. The results of gene expression profiles showed that the exposure 
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of PC12 cells to NPsA induced a general stress condition, because a dose dependent increase in 
expression of genes related to both extrinsic and intrinsic pathways of apoptosiswas was observed 
(Fig. 4.10). The intrinsic pathway initiated by caspase 9 appeared the most activated, however an 
increase in expression of caspase 8 was observed; the overexpression of tardive apoptotic markers, 
such as caspase 3, or other markers playing a key role in cell regulation, such as p53, generally 
indicate a stress condition in the cell. 
 
Fig. 4.10. Analyses of relative gene expression by RTqPCR on PC12 cells treated with NPsA, 
expressed as normalized fluorescence intensity with standard errors as bars. Asterisks indicate 
significant values in comparison to control (NT). * = p<0.05; **= p<0.01; ***=p<0.001). 
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The analyses of activated biochemical patterns by Western Blot allowed to quantitatively measure 
the expression of some key proteins related to cell stress and involved in the apoptosis process, such 
as phosphorylated extracellular signal regulated kinase (pERK), cleaved caspase 3 and cleaved poly 
ADP ribosome phosphorylase (PARP). The comparison of expression profiles of these proteins at 
the different NPsA concentrations yielded information about biochemical and molecular responses 
of PC12 cells. When PC12 cells were treated by NPsA, no significant dose dependent variation in 
comparison to control was detected in pERK at 24 hours, but the amount of this protein 
significantly decreased at 48 hours, remaining lower than at 24 hours (Fig. 4.11). The levels of 
caspase 3 and cleaved PARP did not significantly changed at the concentrations tested, supporting 
the hypothesis that cells were not initiating apoptosis. According to the results of protein markers in 
Fig. 4.11, the cell response appears only time dependent. 
  
Fig. 4.11. Western Blot after SDS-PAGE and densitometric analysis of key proteins related to 
apoptosis (with β-actin as standard marker) in PC12 cells treated with NPsA (50, 75 and 100 µg/ml) 
for 24 and 48 hours. Bars represent standard errors. Asterisks indicate significant values in 
comparison to control (NT). * = p<0.05 
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The same series of analyses perfomed on PC12 cells to characterize the effects of NPsA was 
repeated on OC-k3 cells, in the same experimental conditions. These data allowed to evaluate the 
differences in NPs tolerance of two cell lines representative of inner ear cell populations. 
The viability tests by MTS on OC-k3 cells (Fig. 4.12) revealed that NPsA induced a toxicity dose 
dependent, but not time dependent. The concentration limit after which there was a significant 
decrease of cell viability was 50 µg/ml (p<0.001), both at 24 and 48 hours of treatment. 
Concentrations above 100 µg/ml caused a cell mortality higher than 80%. 
These results are very different from those obtained in PC12 cells: the effects of NPsA may 
therefore depend on the type of cell line used. It was therefore decided to employ for the other tests 
on OC-k3 a narrower concentration range of NPsA, 10-50 µg/ml. 
 
Fig. 4.12. In vitro toxicity of NPsA on OC-k3 cells, expressed as percentage of cell viability vs. 
NPsA concentration. Bars represent the standard errors. Asterisks indicate significant differences in 
comparison to untreated controls (NT) (* = p<0.001). 
 
The cell viability data were compared to those obtained by flow cytometry in OC-k3 cells exposed 
to NPsA for 24 and 48 hours, at a concentration range not causing any significant cell toxicity. 
Generally, the treatment with NPsA did not cause a significant variation of the cell population in 
each phase of the cell cycle (Fig. 4.13). Even at the limit concentration of 50 µg/ml no significant 
increase of the hypodiploid cell number was observed. However, there was a trend in reduction of 
cell population in S and G2/M and an increase in G0/G1, more evident at 48 hours of treatment. 
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Fig. 4.13. Analyses by flow cytometry of OC-k3 cells treated with NPsA at 25 and 50 µg/ml for 24 
and 48 hours. A, B. Number of cells (expressed as counts) in each phase of the cell cycle. For each 
experimental condition, about 20000 events were analysed. NT, untreated control. APOP, 
apoptosis. C, D. Distribution of cells expressed as percentage of gated cells ± standard error in each 
cell cycle phase. 
 
As for PC12 cells, the morphological analyses by phase contrast optical microscopy on OC-k3 cells 
treated with NPsA showed the presence of intracellular vesicles in the perinuclear region: their 
number and size increased with increasing concentrations of NPsA (Fig. 4.14). As previously 
observed for PC12 cells, this dose dependent effect was related to uptake of NPsA inside the cell, 
thus probably related to a response to the osmotic stress caused by NPs treatment; however, the type 
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and role of these vesicles is still unclear. At the NPsA concentrations tested, the size and shape of 
OC-k3 cells was not altered. 
 
Fig. 4.14. Phase contrast images of OC-k3 cells treated with NPsA. Magnification 40x. A. 25 
µg/ml: arrow heads indicate small perinuclear vesicles. B. 50 µg/ml: arrows indicate large vesicles. 
 
The analyses by fluorescence microscopy of OC-k3 cells treated with NPs conjugated with 
rhodamine B at concentrations 25 and 50 µg/ml for 2, 4, 24 and 48 hours confirmed the fast 
internalization of NPs: the signal was clearly visible at 4 hours of treatment (Fig. 4.15). No 
significant differences in internalization times were detected at the two concentrations of NPs plus 
rhodamine B tested. Although a quantitative analysis of fluorescence was not performed, the signals 
resulted more intense at increasing NPs concentration and reached a peak at 24 hours, decreasing at 
48 hours. As observed for PC12 cells, the NPs apparently localized in the perinuclear region but not 
in the positions corresponding to vesicles. 
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Fig. 4.15. Fluorescent microscope images and colour-combined (phase contrast plus fluorescence) 
images of OC-k3 cells treated with 25 and 50 µg/ml NPs conjugated with rhodamine B for 2, 4, 24 
and 48 hours. Magnification 40x. 
 
The results of morphological tests by annexin V-FITC and PI indicated that NPsA up to the 
concentration of 50 µg/ml did not cause cell death by apoptosis (green-red double signal) in OC-k3 
cells treated for 24 and 48 hours, in comparison to untreated controls and to the number of cells still 
adhering to culture flasks after treatment (Fig. 4.16). Cells exhibiting the double signal were in low 
number and almost all detached. The number of cells undergoing apoptosis was not significantly 
different from that of control populations. However, the number of adhering cells progressively 
reduced with increasing concentrations of NPsA. Similarly, the tests with DAPI and phalloidin-
TRITC on OC-k3 cells did not reveal any sign of apoptosis at the NPsA concentration tested (Fig. 
4.17). The cells appeared normal in shape, withouth any significant alterations of cytoskeleton, the 
nuclei were not fragmented and the chromatin was not condensed, as expected in typical apoptotic 
events. 
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Fig. 4.16. Morphological investigations with annexin V-FITC (green) and PI (red) on OC-k3cells 
treated with NPsA 50 µg/ml at 24 and 48 hours. Images a, c, e, g are phase contrast. NT, untreated 
control. White arrows indicate cells in apoptosis or necrosis. Magnification 40x. 
 
Fig. 4.17. Morphological investigations with DAPI(blue) and phalloidin-TRITC (red) on OC-k3 
cells treated with NPsA 50 µg/ml at 24 and 48 hours. Images a, c, e, g are colour-combined DAPI-
phase contrast. NT, untreated control. Magnification 40x. 
 
Concerning gene expression profiles analysed by RTqPCR, the exposure of OC-k3 cells to NPsA at 
concentrations 10 and 25 µg/ml revealed a time dependent increase of gene expression of caspase 8, 
initiator of the extrinsic apoptotic, but a decrease in gene expression of caspase 9, initiator of the 
intrinsic pathway (Fig. 4.18). Genes such as the effector caspase 3 or p53 were overexpressed, again 
in time dependent way. The BAX and Bid genes, involved in the cell response at mitochondrial 
level, resulted significantly overexpressed after 48 hours of treatment.  
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Fig. 4.18. Analyses of relative gene expression by RTqPCR on OC-k3 cells treated with NPsA, 
expressed as normalized fluorescence intensity with standard errors as bars. Asterisks indicate 
significant values in comparison to control (NT). * = p<0.05; **= p<0.01; ***=p<0.001). 
 
The analyses of activated biochemical patterns by Western Blot on OC-k3 did not show any 
increase in expression of protein markers related to apoptosis up to the concentration of 25 µg/ml of 
NPsA, in comparison to untreated controls (Fig.4.19). The level of pERK decreased in a dose and 
time dependent way in comparison to controls; that of cleaved caspase 3 increased only at NPsA 50 
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µg/ml for 48 hours, a concentration which resulted toxic for OC-k3 cells according to the viability 
tests. The same significant trend (p<0.001) was observed for the levels of cleaved PARP. 
 
Fig. 4.19.Western Blot after SDS-PAGE and densitometric analysis of key proteins related to 
apoptosis (with β-actin as standard marker) in PC12 cells treated with NPsA (10, 25 and 50 µg/ml) 
for 24 and 48 hours. Bars represent standard errors. Asterisks indicate significant values in 
comparison to control (NT). * = p<0.001. 
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4.2.2 Characterization of NPsQ  
 
The in vitro analyses performed on NPsQ alone had the aim to verify possible differences in 
comparison to NPsA. Since the two types of nanoparticles have similar physical chemical 
properties, the hypothesis was that the cell response could be affected by the presence of coenzyme 
Q conjugated to NPs. 
In PC12 cells, the treatment with NPsQ at 24 and 48 hours induced an increase of cell viability even 
at high concentrations (Fig. 4.32). The increase in cell viability became significant at 50 µg/ml 
(p<0.05) at 24 and 48 hours and up to 120 µg/ml an increase in cell viability was observed. No cell 
toxicity was observed at doses lower than 150 µg/ml. However, comparing the results at 24 and 48 
hours, the trends appeared rather different, with a slight increase (although not significant) at 48 
hours. Based on the above data, the concentration range chosen for all analyses conducted on NPsQ 
was 25 - 100 µg/ml. 
 
 
Fig. 4.32. In vitro toxicity of NPsQ on PC12 cells, expressed as percentage of cell viability vs. 
NPsQ concentration (µg/ml) at 24 and 48 hours. Bars represent the standard errors. The asterisks 
indicate significant differences in comparison to untreated controls (* = p<0.05; ** = p<0.01; *** = 
p<0.001). 
 
The analyses of cell cycle by flow cytometry indicated that the PC12 cell populations treated with 
NPsQ had a distribution similar to untreated controls, both at 24 and 48 hours (Fig. 4.33). At 24 
hours and 75-100 µg/ml NPsQ the PC12 cell populations showed a slight significant increase 
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(p<0.05) in S phase. For other NPsQ concentrations a progressive decrease in G2/M was observed 
at 24 hours, while at 48 hours a progressive (but not significant) increase was observed at 48 hours. 
No significant increase in hypodiploid population was detected when NPsQ doses or time of 
exposure were increased. 
 
Fig. 4.33. Analyses by flow cytometry of PC12 cells treated with NPsQ (50, 75 and 100 µg/ml) for 
24 and 48 hours. A, B. Number of cells (expressed as counts) in each phase of the cell cycle. For 
each experimental condition, about 20000 events were analysed. NT, untreated control. APOP, 
apoptosis. C, D. Distribution of cells expressed as percentage of cells ± standard error in each cell 
cycle phase. The asterisks indicate significant differences in comparison to untreated controls 
(*=p<0.05). 
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The morphological analyses by annexin V-FITC and PI confirm that at the NPsQ concentrations 
examined (up to 100 µg/ml) no evident apoptosis was detected by fluorescence microscopy (Fig. 
4.34). The PC12 cells treated with NPsQ (Fig. 4.34 F-H) did not show any green stain 
characterizing the initial apoptotic process in comparison to controls where few stained cells are 
detected within a high number of cells (Fig. 4.34 B-D). 
The PC12 cells treated with NPsQ and stained by DAPI and phallodin-TRITC showed a normal 
nucleus and cytoskeleton, very similar to untreated controls (Fig. 4.35). The condition of 
cytoskeleton was not clearly visible because of PC12 cell morphology, but the cell shape was 
preserved at high NPsQ concentration (Fig. 4.35 F-H) at 24 and 48 hours; moreover, nuclei 
appeared roundish and undistorted (Fig. 4.35 E-G). 
 
Fig. 4.34. Morphological investigations with annexin V-FITC (green) and PI (red) on PC12 cells 
treated with NPsQ (100 µg/ml) at 24 and 48 hours. Images a, c, e, g are phase contrast. NT, 
untreated control. Magnification 40x. 
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Fig. 4.35. Morphological investigations with DAPI (blue) and phalloidin-TRITC (red) on PC12 
cells treated with NPsQ (100 µg/ml) at 24 and 48 hours. Images a, c, e, g are colour-combined 
DAPI-phase contrast. NT, untreated control. Magnification 40x. 
 
The analyses on gene expression profiles by RTqPCR showed that the treatment of PC12 cells with 
NPsQ increased the transcription of some apoptosis-related genes (Fig. 4.36). The interaction of 
NPsQ with cells induced an increase in initiatior caspases, especially caspase 9: the levels of 
caspase 9 transcripts increased in a significant way (p<0.001) at 48 hours. After the activation of 
caspase 9, other transcription factors involved in apoptosis, such as BAX ans caspase 3, are slightly 
(but not significantly) overexpressed. The expression of these genes was lower at 48 hours. 
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Fig. 4.36. Analyses of relative gene expression by RTqPCR on PC12 cells treated with NPsQ (25 
and 75 µg/ml) at 24 and 48 hours, expressed as normalized fluorescence intensity with standard 
errors as bars. Asterisks indicate significant values in comparison to control (NT). (* = p<0.05; **= 
p<0.01). 
 
The results of protein expression measured by Western blot were in agreement with the previous 
ones: the apoptotic marker proteins were not significantly overexpressedand were neither dose nor 
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time dependent (Fig. 4.37). The level of cleaved PARP significantly decreased in comparison to 
untreated controls at 24 hours and NPsQ 100 µg/ml (p<0.01) and at 48 hours from 50 µg/ml 
onwards (p<0.05). The levels of pERK also  decreased in a dose and time dependent way.  
 
Fig. 4.37. Western Blot after SDS-PAGE and densitometric analysis of key proteins related to 
apoptosis (with β-actin as standard marker) in PC12 cells treated with NPsQ (50, 75 and 100 µg/ml) 
for 24 and 48 hours. Bars represent standard errors. Asterisks indicate significant values in 
comparison to control (NT). (* = p<0.05; ** = p<0.01). 
 
On OC-k3 cells the NPsQ induced a toxicity dose dependent but not time dependent. The 
concentration causing a first toxic effect on OC-k3 cells treated with NPsQ at 24 and 48 hours was 
50 µg/ml (p<0.001): a 20% decrease in cell viability was detected (Fig. 4.38). Increasing the NPsQ 
concentration to 75 µg/ml, the cell viability decreased to 40% for both 24 and 48 hours (p<0.001) 
and at 100 µg/ml the decrease reached 80%. 
Based on cell viability tests, a concentration range of NPsQ between 10 and 75 µg/ml was chosen 
for the molecular analyses: this range was the best to verify the possible effects of the conjugated 
compound. 
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Fig. 4.38. In vitro toxicity of NPsQ on OC-k3 cells, expressed as percentage of cell viability vs. 
NPsQ concentration (µg/ml) at 24 and 48 hours. Bars represent the standard errors. The asterisk 
indicates significant differences in comparison to untreated controls (* = p<0.001). 
 
The analyses of cell cycle by flow cytometry in OC-k3 cells at 24 and 48 hours was performed at 
NPsQ concentrations 0-50 µg/ml. The results confirmed that NPsQ did not cause apoptosis in OC-
k3 cells and no significant variations were detected in comparison to untreated controls (Fig. 4.39). 
At 24 hours, a slight dose dependent decrease in cell population number in G0/1 and G2/M was 
detected, together with an increase in S. At 48 hours a slight increase was detected in G0/1 and a 
decrease in S and G2/M. 
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Fig. 4.39. Analyses by flow cytometry of OC-k3 cells treated with NPsQ (25 and 50 µg/ml) for 24 
and 48 hours. A, B. Number of cells (expressed as counts) in each phase of the cell cycle. For each 
experimental condition, about 20000 events were analysed. NT, untreated control. APOP, 
apoptosis. C, D. Distribution of cells expressed as percentage of cells ± standard error in each cell 
cycle phase. 
 
The morphological analyses by annexin V-FITC (Fig. 4.40) and PI revealed that NPsQ did not 
induce cell death by apoptosis. There was no evident difference between the number of treated cells 
showing the double stain with annexin V-FITC and PI in comparison to untreated controls (Fig. 
4.39). The stain with DAPI (Fig. 4.41) did not show any evident chromatin condensation or nuclei 
fragmentation, typical of the apoptotic process. However, the number of cells adhering to the 
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substrate was markedly reduced at NPsQ concentration 100 µg/ml (Fig 4.41 E-G). The cell shape 
was preserved and cytoskeleton was not apparently altered by the treatment (Fig. 4.41 F-H). 
 
Fig. 4.40. Morphological investigations with annexin V-FITC (green) and PI (red) on OC-k3 cells 
treated with NPsQ (50 µg/ml) at 24 and 48 hours. White arrowheads indicate cells in apoptosis. 
Images a, c, e, g are phase contrast. NT, untreated control. Magnification 40x. 
 
Fig. 4.41. Morphological investigations with DAPI (blue) and phalloidin-TRITC (red) on OC-k3 
cells treated with NPsQ (50 µg/ml) at 24 and 48 hours. Images a, c, e, g are colour-combined DAPI-
phase contrast. NT, untreated control. Magnification 40x. 
 
For analyses of OC-k3 cells by RTqPCR the NPsQ concentration range employed was 10-25 µg/ml 
(Fig 4.42). Generally, the level of analysed transcripts increased in a dose and time dependent way. 
The level of caspase 8 did not increase significantly, except at 25 µg/ml and 48 hours; the 
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expression of caspase 9 remained similar to the untreated controls. Concerning the genes 
transcribed after the activation of caspase 8 and 9, BAX and Bid followed a similar path, increasing 
in a dose dependent way, significant only at 25 µg/ml and 48 hours. The expression of initiator 
caspase and that of genes regulating the next apoptotic phases appeared in good agreement. Among 
the genes investigated, the most expressed one was the effector caspase 3, significantly expressed 
after 48 hours (p<0.001) at both doses tested. 
 
Fig. 4.42. Analyses of relative gene expression by RTqPCR on OC-k3 cells treated with with NPsQ 
(100 µg/ml) at 24 and 48 hours, expressed as normalized fluorescence intensity with standard errors 
as bars. Asterisks indicate significant values in comparison to control (NT). (* = p<0.05; ** = 
p<0.01; ***=p<0.001). 
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In analyses by Western blot on OC-k3 cells a range of NPsQ concentration 25-75 µg/ml was 
employed. At that range, the results indicated that proteins involved in apoptosis were not 
overexpressed (Fig. 4.43). The level of pERK is more or less similar to untreated controls and that 
of cleaved caspase 3 showed a slight (but not significant) time dependent increase. The same trend 
is observed for cleaved PARP at 24 hours, but a significant increase at 75 µg/ml NPsQ (p<0.001) 
was detected at 48 hours. 
 
Fig. 4.43. Western Blot after SDS-PAGE and densitometric analysis of key proteins related to 
apoptosis (with β-actin as standard marker) in OC-k3 cells treated with NPsQ (25, 50 and 75 µg/ml) 
for 24 and 48 hours. Bars represent standard errors. Asterisks indicate significant values in 
comparison to control (NT). (**= p<0.01; *** = p<0.001). 
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4.2.3 Characterization of NPsD  
 
The same analyses performed on NPSQ were conducted for NPsD with the aim to verify the effects 
of dexamethasone conjugated to NPs in comparison to NPsA, and in order to calculate the range of 
tolerance of these nanoparticles in PC12 and OC-k3 cells for protection tests. However, unlike for 
the other two types of NPs, the effects of NPsD were quite different according to the cell line tested. 
When PC12 were treated with NPsD at different concentrations, a significant toxic effect on cell 
viability was detected at concentrations as low as 10 and 25 µg/ml at 24 hours (p<0.05) (Fig. 4.44). 
This toxic effect was followed by a recovery, restoring the viability at control levels at100 µg/ml. 
The NPsD toxicity apparently reduced in a dose dependent way from 25 to 100 µg/ml for both 
times of exposure. At 48 hours, it increased in a highly significant way (p<0.001) when cells were 
treated from 10 to 75 µg/ml: again, a recovery occurred at 100 µg/ml, but beyond this concentration 
limit the toxicity increased again for both 24 and 48 hours. 
 
Fig. 4.44. In vitro toxicity of NPsD on PC12 cells, expressed as percentage of cell viability vs. 
NPsD concentration (µg/ml) at 24 and 48 hours. Bars represent the standard errors. The asterisks 
indicate significant differences in comparison to untreated controls (* = p<0.05;** = p<0.001). 
 
The preliminary morphological investigations (by annexin V-FITC and PI, and by DAPI and 
phalloidin-TRITC) and the molecular ones (cell cycle by flow cytometry, gene expression by 
RTqPCR and protein expression by Western blot) confirmed the toxic effect of NPsD on PC12 cells 
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even at low concentrations. Based on these data, the protections tests on PC12 cells with CDDP 
(highly toxic at low concentrations for this cells line) were not performed with NPsD. 
In OC-k3 cells the NPsD affect cell viability in a similar way to NPsA and NPsQ, but with a higher 
time dependent toxic effect (Fig. 4.45). At 24 hours, NPsD were not significantly toxic up to 50 
µg/ml: at this concentration a 20% decrease in cell viability was detected in comparison to controls 
(p<0.001). The toxicity of NPsD increased in a significant way (p<0.001) at higher concentrations. 
At 48 hours, from 50 µg/ml the toxicity showed a sharper increase in comparison to 24 hours 
(p<0.001), inducing a 70% vitality decrease at the concentration 75 µg/ml NPsD. 
Based on these results, for the next molecular analyses on OC-k3 the range of NPsD concentrations 
used was 25-75 µg/ml, with the aim to convey a higher drug amounts within the cells and verify 
their effects. The lower NPsD concentrations were excluded because of the very low amount of 
conjugated drug. 
 
 
Fig. 4.45. In vitro toxicity of NPsD on OC-k3 cells, expressed as percentage of cell viability vs. 
NPsD concentration (µg/ml) at 24 and 48 hours. Bars represent the standard errors. The asterisk 
indicates a significant difference in comparison to untreated controls (* = p<0.001). 
 
For the analyses of cell cycle by flow cytometry on OC-k3 cells, the range of NPsD concentrations 
examined was wide (25-75 µg/ml), but no significant variations were detected in the distribution of 
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cell populations in the different phases of the cell cycle (Fig. 4.46). At 24 and 48 hours a slight dose 
dependent increase of hypodiploid cells and a decrease of cells in G2/M was noticed, and a slight 
recovery was observed at 48 hours in G2/M. 
 
Fig. 4.46. Analyses by flow cytometry of OC-k3 cells treated with NPsD (25, 75 and 50 µg/ml) for 
24 and 48 hours. A, B. Number of cells (expressed as counts) in each phase of the cell cycle. For 
each experimental condition, about 20000 events were analysed. NT, untreated control. APOP, 
apoptosis. C, D. Distribution of cells expressed as percentage of cells ± standard error in each cell 
cycle phase. 
 
According to morphological analyses with annexin V-FITC and PI (Fig. 4.47) up to NPsD 
concentration 50 µg/ml, at 24 hours the number of cells exhibiting the double staining (green-red) 
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was not apparently different in comparison to untreated controls (Fig.4.47 F-H). The number of 
cells stained in green-red increased with time, but the differences in comparison to controls were 
hardly visible. At 48 hours, the number of cells undergoing cell division was higher in comparison 
to 24 hours. 
 
 
Fig. 4.47. Morphological investigations with annexin V-FITC (green) and PI (red) on OC-k3 cells 
treated with NPsD (50 µg/ml) at 24 and 48 hours. White arrowheads indicate cells in apoptosis. 
Images a, c, e, g are phase contrast. NT, untreated control. Magnification 40x. 
 
The morphological investigations by DAPI and phalloidin-TRITC did not reveal any difference in 
the aspect of cytoskeleton and/or nucleus (Fig. 4.48). At 50 µg/ml NPsD the cells maintained their 
normal shape and the cytoskeleton fibres appeared long and intact. No chromatin condensation or 
enlargement of nuclei was visible, thus cells did not show any sign of apoptosis even at high NPsD 
doses. 
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Fig. 4.48. Morphological investigations with DAPI (blue) and phalloidin-TRITC (red) on OC-k3 
cells treated with NPsD (50 µg/ml) at 24 and 48 hours. Images a, c, e, g are colour-combined DAPI-
phase contrast. NT, untreated control. Magnification 40x. 
 
When gene expression profiles were analysed by RTqPCR in OC-k3 cells exposed to NPsD, all 
transcripts examined closely followed the levels of controls for both NPsD concentrations analysed 
(25 and 50 µg/ml) and for both exposure times, 24 and 48 hours (Fig. 4.48).Only caspase 3 resulted 
significantly overexpressed at 24 hours (p<0.05): all other genes had a lower time dependent 
expression in comparison to controls. 
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Fig. 4.49. Analyses of relative gene expression by RTqPCR on OC-k3 cells treated with NPsD (25 
and 50 µg/ml) at 24 and 48 hours, expressed as normalized fluorescence intensity with standard 
errors as bars. Asterisks indicate significant values in comparison to control (NT). (* = p<0.05; **= 
p<0.01). 
 
The densitometric analyses of Western blot of apoptotic markers in OC-k3 cells treated with NPsD 
confirmed the results obtained by RTqPCR: the expression of proteins directly involved in the 
apoptotic process, such as cleaved caspase 3 and PARP, was significantly reduced in a dose and 
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time dependent way, in comparison to controls. However, the level of pERK increased at 48 hours 
and at higher NPsD doses. 
 
Fig. 4.50. Densitometric analysis of Western blot of key proteins related to apoptosis in OC-k3 cells 
treated with NPsD (25 and 50 µg/ml) for 24 and 48 hours. Bars represent standard errors. Asterisks 
indicate significant values in comparison to control (NT). (* = p<0.05; ** = p<0.001). 
 
4.3 Characterization of cisplatin in vitro 
 
The PC12 cells resulted very sensitive to treatment with CDDP. A significant 20% decrease 
(p<0.001) in cell viability was detected at concentration 5 µM for 24 hours, and more than 70% 
(p<0.001) at 25 µM. When the exposure time was increased to 48 hours, the toxicity increased to 
60% at 5 µM and reached a highly significant peak of 89% (p<0.001) at 25 µM. Therefore CDDP 
induced a dose and time dependent toxicity on PC12 cells.  
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Fig. 4.20. In vitro toxicity of CDDP on PC12 cells, expressed as percentage of cell viability vs. 
CDDP concentration (µM). Bars represent the standard errors. The asterisk indicates significant 
differences in comparison to untreated controls (* = p<0.001). The dot indicates significant 
differences between 48 and 24 hours of exposure (• = p<0.05). 
 
The analyses of cell cycle by flow cytometry in PC12 cells treated with CDDP at 24 an 48 hours 
(Fig. 4.21) showed alterations in the distribution of cell populations in comparison to controls. At 
24 hours of treatment, for low CDDP concentrations (2.5 and 5 µM) a progressive increase in the 
number of cells in S and a decrease of those in G2/M was detected. For concentrations from 13 µM 
on, the number of cells in S sharply decreased while a significant increase since the concentration 5 
µM of hypodiploid cells was observed. After 48 hours there is a significant decrease (p<0.001) in S 
and G2/M cell population from the CDDP concentration 13 µM onward and a significant increase 
in the number of hypodiploid cells (p<0.001). 
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Fig. 4.21. Analyses by flow cytometry of PC12 cells treated with CDDP from 2.5 to 50 µM for 24 and 48 hours. A, B. Number of cells (expressed 
as counts) in each phase of the cell cycle. For each experimental condition, about 20000 events were analysed. NT, untreated control. APOP, 
apoptosis. C, D. Distribution of cells expressed as percentage of cells ± standard error in each cell cycle phase. The asterisk indicates significant 
differences in comparison to untreated controls (* = p<0.001). 
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The induction of apoptotic process by CDDP in PC12 cells was confirmed in morphological tests.  
The results of morphological tests by annexin V-FITC and PI on PC12 cells exposed to CDDP 5 
µM for 24 hours showed that most adhering cells were stained in green because of binding of 
annexin V to phosphatidylserine exposed on the cell membrane in the early phases of apoptosis 
(Fig. 4.22). PC12 are cells that easily detatch from the culture flask if exposed to a high stress 
condition. Therefore the higher cytotoxicity experiments are usually performed after slide fixation. 
For this reason after 48 hours of treatment with higly cytotoxic doses of CDDP (13 and 25 µM) it 
was really difficult to obtain images of the cells treated and they are not reported in Fig. 4.22.  
 
Fig. 4.22. Morphological investigations with annexin V-FITC (green) and propidium iodide (PI) 
(red) on PC12 cells treated with CDDP (from 5 to 25 µM) at 24 and 48 hours. Images a, c, e, g, i, m 
are phase contrast. NT, untreated control. Magnification 40x. 
 
The tests with DAPI and phalloidin-TRITC on PC12 cells at the same CDDP concentrations and 
time of exposure showed a shrinkage in the few cells still adhering to the substrate, a reduction in 
cytoskeleton and a highly reduced cytoplasm, hardly visible around the nucleus (Fig. 4.23). Several 
 78 
 
nuclei appeared fragmented and multi-lobed, showing a chromatin condensation typical of the 
apoptotic process. At increasing CDDP concentration the number of adhering cells sharply 
decreased and the last identifiable cells had highly reduced cytoplasms and condensed nuclei. 
 
Fig. 4.23. Morphological investigations with DAPI (blue) and phalloidin-TRITC (red) on PC12 
cells treated with CDDP(5, 13 and 25 µM) at 24 and 48 hours. Images a, c, e, g, i, m, o, q are 
colour-combined DAPI-phase contrast. NT, untreated control. Magnification 40x. 
 
In the analysis of gene expression the same genes previously examined for NPsA were investigated 
for CDDP in PC12 cells: the expression of these transcripts significantly increased in a dose and 
time dependent way (Fig. 4.24). At the lowest CDDP concentration tested (5 µM) the increased 
gene expression was significant (p<0.05) at 48 hours for almost all genes examined. At higher 
CDDP concentrations, a significant increase in gene expression was detected, also time dependent. 
The markers of early apoptotic process, such as caspase 8 and 9, at CDDP 5 µM after 48 hours were 
significantly overexpressed (p<0.05). Caspase 3 was significantly overexpressed already at 5 µM 
and 24 hours. The levels of p53 increased in a dose and time dependent way, but the increase was 
significant (p<0.001) only at 25 µM after 24 hours. The transcript of BAX was significantly 
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expressed since the CDDP concentration 5 µM at 24 h (p<0.05) onwards in a dose and time 
dependent way.  
 
Fig. 4.24. Analyses of relative gene expression by RTqPCR on PC12 cells treated with CDDP (5-25 
µM, expressed as normalized fluorescence intensity with standard errors as bars. Asterisks indicate 
significant values in comparison to control (NT). * = p<0.05; **= p<0.01; ***=p<0.001). 
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The data of relative gene expression by RTqPCR agreed with those obtained by Western blot: all 
proteins analysed were overexpressed at all CDDP concentrations and time of exposure examined. 
The level of expression of PARP, marker of DNA damage, after CDDP treatment, resulted 
significantly higher in comparison to controls only at 13 µM (p<0.01); the level of caspase 3 was 
also significantly higher since CDDP 5 µM and 48 hours (p<0.05) onwards. The level of pERK 
protein was significantly overexpressed (p<0.001) for all the CDDP concentration tested at 24 
hours. after 48 hours the levels of pERK decreased compared to the same values at 24 hours, but its 
expression remain higher than the untreated control (NT). 
 
Fig. 4.25. Western Blot after SDS-PAGE and densitometric analysis of key proteins related to 
apoptosis (with β-actin as standard marker) in PC12 cells treated with CDDP (5, 13 and 25 µM) for 
24 and 48 hours. Bars represent standard errors. Asterisks indicate significant values in comparison 
to control (NT). (* = p<0.05;**=p<0.01; ***=p<0.001). 
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In OC-k3 cells the exposure to CDDP caused a toxicity dose and time dependent: CDDP was 
already significantly toxic at 13 µM, causing a 12% decrease of cell viability (p<0.001). The toxic 
effect increased along with CDDP concentrations (Fig. 4.26). At 48 hours the toxicity was 
significant at 5 µM, with a 12% decrease of cell viability (p<0.001) and a 60% decrease at 13 µM a 
48 ore (p<0.001).  
 
Fig. 4.26. In vitro toxicity of CDDP on OC-k3 cells, expressed as percentage of cell viability vs. 
CDDP concentration (µM). Bars represent the standard errors. The asterisk indicates significant 
differences in comparison to untreated controls (* = p<0.001). The dot indicates significant 
differences at 48 hours of exposure (• = p<0.05). 
 
The analyses of cell cycle by flow cytometry in OC-k3 cells treated with CDDP showed a 
significant increase of the hypodiploid population at 5 µM and 24 hours (Fig. 4.27), increasing in a 
dose and time dependent way. At 48 hours the number of cells in G0/G1 phase significantly 
decrease at the concentrations 2.5 – 25 µg/ml (p<0.001), while at the same concentration there is an 
increase of the S phase cell (p<0.001). In G2/M phase a general decrease in cell number was 
observed from the 13 µM. At 24 hours the increase in hypodiploid cell population (thus undergoing 
apoptosis) was significant since the CDDP concentration 13 µM (p<0.001) onwards; at 48 hours the 
increase of hypodiploid population is significant (p<0.001) since the concentration 2.5 µM of 
CDDP.  
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Fig. 4.27. Analyses by flow cytometry of OC-k3 cells treated with CDDP from 2.5 to 50 µM for 24 and 48 hours. A, B. Number of cells (expressed 
as counts) in each phase of the cell cycle. For each experimental condition, about 20000 events were analysed. NT, untreated control. APOP, 
apoptosis. C, D. Distribution of cells expressed as percentage of cells ± standard error in each cell cycle phase. The asterisk indicates significant 
differences in comparison to untreated controls (* = p<0.001). 
 83 
 
The results of morphological tests by annexin V-FITC and PI on OC-k3 cells exposed to CDDP 
show a cell death dose and time dependent by apoptosis or necrosis. In controls, a few cells were 
positive to annexin V-FITC and PI treatment: at 5 µM and 24 hours few cells were positive to 
annexin V-FITC and PI (Fig. 4.28). The signal increased with CDDP concentration: at 24 hours, a 
diffused green staining at 13 µM indicated that most cells were entering apoptosis, and at 25 µM 
most cells were dying and detaching from substrate: the few still adhering showed a double stain 
(green and red), indicating that the cell membrane was breaking apart and cell death was under way. 
A remarkable worsening of these conditions at 48 hours, with a low number of adhering cells and a 
higher number showing annexin V-FITC green signals at low concentrations (Fig. 4.28 J). 
 
Fig. 4.27. Morphological investigations with annexin V-FITC (green) and PI (red) on OC-k3 cells 
treated with CDDP (5, 13 and 25 µM) at 24 and 48 hours. Images a, c, e, g, i, m, o, q are phase 
contrast. NT, untreated control. Magnification 40x. 
 
The effects of CDDP treatment on OC-k3 cells were visible also on cytoskeleton, morphologically 
analysed by DAPI and phalloidin TRITC: marked alterations were observe in cytoskeleton as well 
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as in cell nuclei (Fig. 4.29). At 24 hours the normal shape of OC-k3 cells, long and narrow with 
long microtubules (Fig. 4.29B), was altered at 5 µM, the lowest CDDP concentration: cells 
appeared enlarged and roundish, with swollen nuclei (Fig. 4.29F). At 13 µM and 24 hours, or at 48 
hours, these effects were more evident: the cytoskeleton fibers were shorter and thicker, and 
chromatin appeared fragmented within the nuclei (Fig.4.29 H-L). At increasing concentration and 
time of exposure the few adhering cells were completely distorted, with scarce cytoplasm and 
multi-lobed nuclei (Fig.4.29 N-P). 
 
Fig. 4.29. Morphological investigations with DAPI (blue) and phalloidin-TRITC (red) on OC-k3 
cells treated with CDDP (5, 13 and 25 µM) at 24 and 48 hours. Images a, c, e, g, i, m, o, q are 
colour-combined DAPI-phase contrast. NT, untreated control. Magnification 40x. 
 
As for PC12 cells, the analyses by RTqPCR showed that CDDP induced in OC-k3 cells an 
overexpression of genes related to apoptosis in a dose and time dependent way (Fig. 4.30). The 
gene expression profiles appeared homogeneous in their response to treatment, with a gradual 
increase in all analysed transcripts. In OC-k3 a higher activation of the extrinsic pathway to 
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apoptosis was initially observed, with a significant increase of caspase 8 levels at 5 µM (p<0.05), 
while the expression of caspase 9 was significantly higher only at 25 µM after 48 hours (p<0.01). 
Concerning the other genes involved in the late apoptotic process (p53, BAX, Bid and caspase 3) an 
overexpression was observed increasing the concentration of CDDP, reaching a high significance 
(p<0.001) at 25 µM and 24 hours. 
 
Fig. 4.30. Analyses of relative gene expression by RTqPCR on OC-k3 cells treated with CDDP (5, 
13 and 25 µM) expressed as normalized fluorescence intensity with standard errors as bars. 
Asterisks indicate significant values in comparison to control (NT). (* = p<0.05; **= p<0.01; 
***=p<0.001). 
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Also in OC-k3 cells the results of gene expression analyses agreed with those obtained by Western 
blot. The analyses of apoptotic markers at low CDDP concentration revealed a significant increase 
in pERK (p<0.05), caspase 3 (p<0.01) and PARP (p<0.001), in a dose and time dependent way 
(Fig. 4.31). The protein expression matched that of the transcripts examined by RTqPCR, indicating 
that cells entered apoptosis at low CDDP concentration. In detail, at 24 hours the level of cleaved 
caspase 3 was already significant at low CDDP concentration, indicating an advance apoptosis of a 
large number of cells. The cleaved PARP underwent a sharp increase at CDDP 25 µM at both 24 
and 48 hours, indicating that DNA repair mechanisms were highly impaired by CDDP activity. 
 
Fig. 4.31. Western Blot after SDS-PAGE and densitometric analysis of key proteins related to 
apoptosis (with HSP 70as standard marker) in OC-k3 cells treated with CDDP (5, 13 and 25 µM) 
for 24 and 48 hours. Bars represent standard errors. Asterisks indicate significant values in 
comparison to control (NT) (**=p<0.01; ***=p<0.001). 
 
* 
* 
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4.4 Protection analyses  
 
For co-treatment tests of in vitro cell protection, cell lines were pre-treated for 24 hours with NPsQ 
or NPsD at different concentrations and afterwards with CDDP at different concentrations for 24 
and 48 hours: the purpose was to obtain a full interaction between cells and NPs conjugated with 
pharmacological drugs, and therefore a maximum protection against CDDP cytotoxic effects. The 
only reported data were those concerning CDDP concentrations at which protective effects were 
detected in co-treatment with NPsD or NPsQ. 
 
4.4.1 Experiments with NPsQ and CDDP  
 
In co-treatment viability tests, the PC12 cells were pre-treated for 24 hours with NPsQ (25-100 
µg/ml), then co-treated with CDDP 5 µM and the same NPsQ concentrations for 24 and 48 hours. A 
time dependent protective effect was detected, with an increase of cell viability in comparison to 
cells treated only with CDDP (Fig. 4.51). After 24 hours of co-treatment, from NPsQ 25 µg/ml 
onwards, a recovery of cell viability was observed which became significant at NPsQ 75-100 µg/ml 
(p<0.05), restoring the viability to values similar to controls. After 48 hours of co-treatment, CDDP 
5 µM induced a 60% decrease in cell viability. The protective effect of NPsQ was observed from 25 
µg/ml (p<0.01) and increased for higher NPsQ concentrations, 75-125 µg/ml (p<0.001). Data 
obtained at higher CDDP concentrations did not show any protective effect at all NPsQ 
concentrations tested (data not reported). 
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Fig. 4.51. Viability of PC12 cells pre-treated for 24 hours with NPsQ (25-100 µg/ml), then co-
treated with CDDP 5 µM and the same NPsQ concentrations for 24 and 48 hours. Bars represent the 
standard errors. NT: untreated controls. Asterisks indicate significant differences in comparison to 
CDDP alone. (* = p<0.05 ; ** = p<0.01; ***=p<0.001). 
 
The analyses of cell cycle by flow cytometry showed that CDDP 5 µM was able to impair the 
distribution of PC12 cell populations in the different phases of the cell cycle, while the co-treatment 
with NPsQ did not induce a significant recovery in comparison to untreated controls (Fig. 4.52). At 
24 hours, CDDP alone induced an increase in hypodiploid cell population and of the number of 
cells in S, with a consequent decrease of the number of cells in G0 and G2/M. When PC12 cells 
were pre-treated with NPsQ 25 and 75 µg/ml, only a slight decrease of hypodiploid cell population 
was observed for NPsQ 25 µg/ml. At 48 hours, CDDP caused a further increase of the hypodiploid 
cell population and of the number of cells in G0 and G2/M. Again, at this time of exposure NPsQ 
were not apparently able to provide any protection against CDDP negative effects on PC12 cell 
cycle. 
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Fig. 4.52. Analyses by flow cytometry of PC12 cells pre-treated for 24 hours with NPsQ (25 and 75 
µg/ml), then co-treated with CDDP 5 µM and the same NPsQ concentrations for 24 and 48 hours. 
A, B. Number of cells (expressed as counts) in each phase of the cell cycle. For each experimental 
condition, about 20000 events were analysed. NT, untreated control. APOP, apoptosis. C, D. 
Distribution of cells expressed as percentage of cells ± standard error in each cell cycle phase.  
 
In treatments with CDDP 5 µM a sharp decrease in adhering cells was observed, more evident at 48 
hours (Fig. 4.53). The number of adhering cells increased in co-treatments with NPsQ 75 µg/ml 
(Fig. 4.53 N-P).The normal shape of PC12 cells, roundish and flattened, changed after CDDP 
treatment and cells appeared smaller and round even in co-treatments. At 48 hours of co-treatment 
with NPsQ 75 µg/ml, in comparison to CDDP alone a lower number of multi-lobed nuclei was 
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observed in cells. The cytoskeleton and the amount of cytoplasm inside the cells appeared 
unchanged in co-treatments in comparison to CDDP alone. 
 
Fig. 4.53. Morphological investigations with DAPI (blue) and phalloidin-TRITC (red) on PC12 
cells pre-treated for 24 hours with NPsQ (25 and 75 µg/ml), then co-treated with CDDP 5 µM and 
the same NPsQ concentrations for 24 and 48 hours. Images a, c, e, g, i, k, m, o are colour-combined 
DAPI-phase contrast. NT, untreated control. Magnification 40x. 
 
The gene expression analyses by RTqPCR on PC12 cells pre-treated for 24 hours with NPsQ, then 
co-treated with CDDP 5 µM for 24 and 48 hours, did not reveal any protective effect of NPsQ 
against CDDP, but the cell response significantly changed in a time dependent way (Fig. 4.54). The 
treatment with CDDP 5 µM induced an increase in expression of all genes related to apoptosis, at 
both 24 and 48 hours. After 24 hours of co-treatment the expression of the analysed genes is similar 
or higher than that with CDDP alone. In co-treatment with NPsQ 25 µg/ml the caspase 8 caspase 9 
genes were both overexpressed in comparison to CDDP alone. The BAX, p53 and caspase 3 further 
increased their overexpression in co-treatments with NPsQ 75 µg/ml. At 48 hours of co-treatment, 
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all analysed genes showed a marked decrease in expression in comparison to 24 hours and to CDDP 
alone, except for caspase 3. In co-treatments with NPsQ 25 and 75 µg/ml the expression of caspase 
8 and BAX was even lower than in untreated controls (p<0.001).  
 
Fig. 4.54. Analyses of relative gene expression by RTqPCR on PC12 cells pre-treated for 24 hours 
with NPsQ (25 and 75 µg/ml), then co-treated with CDDP 5 µM and the same NPsQ concentrations 
for 24 and 48 hours, expressed as normalized fluorescence intensity with standard errors as bars. 
Asterisks indicate significant values in comparison to CDDP 5 µM (* = p<0.05; **= p<0.01; 
***=p<0.001) 
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Data of protein expression markers related to apoptosis analysed by Western blot in PC12 cells pre-
treated for 24 hours with NPsQ, then co-treated with CDDP and NPsQ for 24 and 48 hours 
indicated a time dependent cell response to co-treatments (Fig. 4.55). At both 24 and 48 hours 
CDDP induced a marked expression increase of the analysed proteins. At 24 hours of co-treatment 
the level of cleaved caspase 3 increased at increasing concentrations of NPsQ. The level of cleaved 
PARP decreased at 24 hours with significant values at the highest NPsQ concentration (p<0.05). 
The levels of pERK decreased at 24 hours at decreasing NPsQ concentrations (p<0.01). At 48 hours 
an improving of protection was detected in co-treatments, with levels of expression of all analysed 
proteins significantly lower than at 24 hours. 
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Fig. 4.55. Western Blot after SDS-PAGE and densitometric analysis of key proteins related to 
apoptosis (with HSP-70 as standard marker) inPC12 cells pre-treated for 24 hours with NPsQ (25 
and 75 µg/ml), then co-treated with CDDP 5 µM and the same NPsQ concentrations for 24 and 48 
hours. Bars represent standard errors. Asterisks indicate significant values in comparison to CDDP 
5 µM (* = p<0.05; **=p<0.01; ***p<0.001).  
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Based on the results of viability assay with NPsQ on OC-k3 cells, it was decided to use the NPsQ 
concentration 10-25-50 µg/ml in the co-treatments, against the CDDP 5 and 13 µM.  
On OC-k3 cells the co-treatments with NPsQ were protective only in comparison to CDDP 5 µM 
(Fig.4.56). At 24 hours of co-treatment a slight recovery of cell viability at NPsQ 10-25 µg/ml was 
observed. At NPsQ 50 µg/ml the cell viability decreased at lower levels in comparison to CDDP 
5µM. At 48 hours CDDP was more toxic and in co-treatments a significant recovery was observed 
only at NPsQ 10 µg/ml (p<0.05). A further decrease in cell viability appeared at higher 
concentrations of CDDP, at both 24 and 48 hours, and co-treatments with NPsQ did not induce any 
significant recovery. 
 
Fig. 4.56. Viability of OC-k3 cells pre-treated for 24 hours with NPsQ (NPsQ10) (10-50 µg/ml), 
then co-treated with CDDP 5 µM and the same NPsQ concentrations for 24 and 48 hours. Bars 
represent the standard errors. NT: untreated controls. Asterisks indicate significant differences in 
comparison to CDDP alone. (* = p<0.05). 
 
The analyses by flow cytometry on OC-k3 co-treated cells showed that CDDP 5 µM induced a 
change in cell population distribution at 24 hours, with a significant decrease of the number of cells 
in G0 and an increase in S and G2 (Fig. 4.57). At 24 hours the effect of co-treatments is observed 
only at the NPsQ concentration 25 µg/ml, inducing a slight (although not significant) decrease in 
number of cells in S and an increase in G2/M compared to CDDP only. At 48 hours, CDDP 5 µM 
induced a sharp decrease in number of cells in G0 and S, and an increase in G2/M and hypodiploid 
cell population. No significant recovery of these adverse effects was detected in co-treatments with 
NPsQ. 
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Fig. 4.57. Analyses by flow cytometry of OC-k3 cells pre-treated for 24 hours with NPsQ (10 and 
25 µg/ml), then co-treated with CDDP 5 µM and the same NPsQ concentrations for 24 and 48 
hours. A, B. Number of cells (expressed as counts) in each phase of the cell cycle. For each 
experimental condition, about 20000 events were analysed. NT, untreated control. APOP, 
apoptosis. C, D. Distribution of cells expressed as percentage of cells ± standard error in each cell 
cycle phase.  
 
In morphological investigations with annexin V-FITC and PI on OC-k3 cells co-treated with NPsQ 
and CDDP, after 24 hours od co-treatment no significant differences were detected between 
untreated controls, CDDP 5 µM and co-treatments (Fig. 4.58). After 48 hours of exposure to CDDP 
most cells were positive to annexin V-FITC and PI, indicating an advanced apoptosis. In co-
treatments a slight reduction of the cells in apoptosis, showing green or double stains (initial 
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apoptosis) was detected at NPsQ 10 µg/ml and 48 hours of co-treatment. At 25 µg/mlNPsQan 
increase of cells showing the double stain was observed. 
 
Fig. 4.58. Morphological investigations with annexin V-FITC (green) and PI (red) on OC-k3 cells 
pre-treated for 24 hours with NPsQ (10 and 25 µg/ml), then co-treated with CDDP 5 µM and the 
same NPsQ concentrations for 24 and 48 hours. White arrowheads indicate cells in apoptosis. 
Images a, c, e, g, i, k, m, o are phase contrast. NT, untreated control. Magnification 40x. 
 
The morphological investigations with DAPI and phalloidin-TRITC revealed that co-treatments 
were not able to protect cells from alterations induced by CDDP (Fig. 4.59). The OC-k3 cells, either 
treated with CDDP or co-treated, appeared enlarged and flattened: the cytoskeleton fibres were 
shorter and nuclei were larger and multi-lobed. These alterations were more evident after 48 hours 
of co-treatment in comparison to 24 hours. 
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Fig. 4.59. Morphological investigations with DAPI (blue) and phalloidin-TRITC (red) on OC-k3 
cells pre-treated for 24 hours with NPsQ (5 and 10 µg/ml), then co-treated with CDDP 5 µM and 
the same NPsQ concentrations for 24 and 48 hours. Images a, c, e, g, i, k, m, o are colour-combined 
DAPI-phase contrast. NT, untreated control. Magnification 40x. 
 
The analyses of relative gene expression by RTqPCR on OC-k3 cells pre-treated with NPsQ, then 
co-treated with CDDP and NPsQ for 24 and 48 hours showed that co-treatments with NPsQ 
significantly reduced the expression of genes related to apoptosis at 24 hours in comparison to 48 
hours (Fig. 4.60). The expression of transcripts of caspase 8 and 9 at 24 hours in co-treatments was 
significantly reduced (p<0.01) in comparison to CDDP alone. The same trend was observed for late 
apoptotic markers such as Bid (p<0.05), p53 (p<0.05) and BAX. For the caspase 3 gene, at 24 hours 
an increase of the expression level was instead observed, significant at NPsQ 25 µg/ml. At 48 hours 
all transcripts of genes related to apoptosis were generally expressed at a higher level than at 24 
hours. 
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Fig. 4.60. Analyses of relative gene expression by RTqPCR on OC-k3 cells pre-treated for 24 hours 
with NPsQ (10 and 25 µg/ml), then co-treated with CDDP 5 µM and the same NPsQ concentrations 
for 24 and 48 hours, expressed as normalized fluorescence intensity with standard errors as bars. 
Asterisks indicate significant values in comparison to CDDP 5 µM (* = p<0.05; **= p<0.01; 
***=p<0.001). 
 
  
*** 
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The results of analyses of protein expression markers related to apoptosis by Western blot in OC-k3 
cells pre-treated for 24 hours with NPsQ, then co-treated with CDDP and NPsQ for 24 and 48 
hours, at 24 hours CDDP did not induce an increase in cleaved caspase 3 or pERK in comparison to 
untreated controls (Fig. 4.61). In the same way, in co-treatments at 24 hours no increase of the 
cleaved protein is detected. At 48 hours the cleaved caspase 3 was significantly overexpressed with 
CDDP alone in comparison to untreated controls, but a decrease in expression dependent on NPsQ 
was observed in co-treatments The marker pERK was significantly overexpressed in co-treatments 
at 24 hours with NPsQ both 10 µg/ml (p<0.01) and 25 µg/ml (p<0.001). After 48 hours of treatment 
pERK was less expressed in comparison to 24 hours (p<0.01) and to CDDP alone (p<0.01). PARP 
level decreased in the co-treatments compared to the CDDP alone with NPsQ 25 µg/ml at 24 hours 
(p<0.01). 
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Fig. 4.61. Western Blot after SDS-PAGE and densitometric analysis of key proteins related to 
apoptosis (with HSP-70 as standard marker) in PC12 cells pre-treated for 24 hours with NPsQ (10 
and 25 µg/ml), then co-treated with CDDP 5 µM and the same NPsQ concentrations for 24 and 48 
hours. Bars represent standard errors. Asterisks indicate significant values in comparison to CDDP 
5 µM (* = p<0.05; **=p<0.01; *** = p<0.001).  
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4.4.2 Experiments with NPsD and CDDP  
 
In protection experiments, NPsD were able to exert a protective effect on OC-k3 cells against a 
highly toxic CDDP concentration, 13 µM. In viability tests, at 24 hours of co-treatment no 
significant recovery of cell viability was observed in comparison to CDDP alone: there was a slight 
(but not significant) decrease, dependent on NPsD concentration (Fig. 4.62). At 48 hours of co-
treatment, a recovery of cell viability was observed from NPsD 10 µg/ml compared to the CDDP 13 
µM alone, which became significant at NPsQ 25 and 50 µg/ml.  
 
 
Fig. 4.62. Viability of OC-k3 cells pre-treated for 24 hours with NPsD (10, 25 and 50 µg/ml), then 
co-treated with CDDP 5 µM and the same NPsD concentrations for 24 and 48 hours. Bars represent 
the standard errors. NT: untreated controls. An asterisk indicates a significant difference in 
comparison to CDDP 13 µM (* = p<0.001). 
 
The analysis of cell cycle by flow cytometry in OC-k3 cells pre-treated for 24 hours with NPsD and 
then co-treated with CDDP and the same NPsD concentrations for 24 and 48 hours confirmed the 
dose and time dependent response of cells to co-treatments (Fig.4.63). In the first 24 hours, CDDP 
induced a significant increase in the number of hypodiploid cells and of those in S, together with a 
decrease of those in G0. At 48 hours these effects were more evident, with a significant number of 
cells in apoptosis and a decrease of the number of cells in all other phases of the cell cycle. The co-
treatment with NPsD from 10 µg/ml onwards induced a reduction in the number of hypodiploid 
cells, but this reduction was not significant at any time of exposure examined. With increasing 
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concentrations of NPsD a time dependent recovery of cells was observed in G2/M, which became 
highly significant at NPsD 25 and 50 µg/ml (p<0.001) at 48 hours of co-treatment.  
 
Fig. 4.63. Analyses by flow cytometry of OC-k3 cells pre-treated for 24 hours with NPsD (10 and 
25 µg/ml), then co-treated with CDDP 5 µM and the same NPsD concentrations for 24 and 48 
hours. A, B. Number of cells (expressed as counts) in each phase of the cell cycle. For each 
experimental condition, about 20000 events were analysed. NT, untreated control. APOP, 
apoptosis. C, D. Distribution of cells expressed as percentage of cells ± standard error in each cell 
cycle phase. An asterisk indicates a significant difference in comparison to CDDP 13 µM (* = 
p<0.05). 
The morphological investigations with annexin V-FITC and PI on OC-k3 cells pre-treated for 24 
hours with NPsD, then co-treated with CDDP and NPsQ for 24 and 48 hours, revealed a marked 
time dependent improvement of cell conditions in comparison to CDDP. After 24 hours of 
treatment with CDDP 13 µM, OC-k3 cells appeared deformed and enlarged: many of them were 
positive to annexin V-FITC and PI (Fig. 4.64). At the same time of exposure in co-treatments with 
NPsD 25 and 50 µg/ml a decrease in the number of double stained cells was detected. At 48 hours 
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of treatment with CDDP 13 µM, the number of cells entering apoptosis increased. In co-treatments 
the OC-k3 cells were more numerous and similar to untreated controls. However, the majority of 
cells appeared elongated and adhering to the substrate: only the roundish ones appeared double 
stained, depending on NPsD increasing concentrations. 
 
Fig. 4.64. Morphological investigations with annexin V-FITC (green) and PI (red) on OC-k3 cells 
pre-treated for 24 hours with NPsD (25 and 50 µg/ml), then co-treated with CDDP 13 µM and the 
same NPsD concentrations for 24 and 48 hours. White arrowheads indicate cells in apoptosis. 
Images a, c, e, g, i, m, o, q are phase contrast. NT, untreated control. Magnification 40x. 
 
The morphological investigations with DAPI and phalloidin-TRITC on OC-k3 cells, pre-treated for 
24 hours with NPsD, then co-treated with CDDP and NPsQ for 24 and 48 hours, revealed that at 24 
hours of treatment with CDDP 13 µM most cells were deformed, with very enlarged nuclei and 
shorter cytoskeletal fibres (Fig. 4.65). Some multi-lobed nuclei were also visible. These effects 
were more evident at 48 hours: only few adhering cells were visible and those still attached to the 
substrate were swollen, with frayed cytoskeleton, scarce cytoplasm and multi-lobed nuclei (Fig. 
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4.65 H). In co-treatments with NPsD, the OC-k3 cells were more similar to untreated controls: the 
number of adhering cells was higher, most cells appeared elongated again and only few had multi-
lobed nuclei. 
 
Fig. 4.65. Morphological investigations with DAPI (blue) and phalloidin-TRITC (red) on OC-k3 
cells pre-treated for 24 hours with NPsD (25 and 50 µg/ml), then co-treated with CDDP 13 µM and 
the same NPsD concentrations for 24 and 48 hours. Images a, c, e, g, i, m, o, q are colour-combined 
DAPI-phase contrast. NT, untreated control. Magnification 40x. 
 
The expression of genes involved in apoptosis, investigated by RTqPCR on OC-k3 cells pre-treated 
with NPsD 25 and 50 µg/ml, then co-treated with CDDP 13 µM and the same concentrations of 
NPsD for 24 and 48 hours, indicated that all transcripts were underexpressed in co-treatments with 
NPsD in comparison to CDDP 13 µM (Fig. 4.66). The NPsD concentration with the lower gene 
expression in comparison to CDDP was 25 µg/ml. The caspase 8 gene was significantly 
underexpressed in comparison to CDDP 13 µM only at 48 hours (p<0.001). The genes involved in 
the apoptotic cascade followed the same trend: Bid (p<0.01), BAX (p<0.001) and caspase 3 
 105 
 
(p<0.001) were significantly underexpressed at 48 hours of co-treatement at NPsD 25 µg/ml. The 
same trend was observed for the antitumoral gene p53. 
 
Fig. 4.66. Analyses of relative gene expression by RTqPCR on OC-k3 cells pre-treated for 24 hours 
with NPsD (25 and 50 µg/ml), then co-treated with CDDP 13 µM and the same NPsQ 
concentrations for 24 and 48 hours, expressed as normalized fluorescence intensity with standard 
errors as bars. Asterisks indicate significant values in comparison to CDDP 13 µM (* = p<0.05; **= 
p<0.01; ***=p<0.001). 
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The results of analyses of protein markers related to apoptosis by Western blot in OC-k3 cells pre-
treated for 24 hours with NPsD, then co-treated with CDDP and NPsD for 24 and 48 hours, 
generally showed a protective effect against the chemotherapeutic drug (Fig. 4.67). The CDDP 13 
µM caused an increase of cleaved caspase 3, pERK and PARP both at 24 and 48 hours of treatment. 
The co-treatment with NPsD reduced the expression of these apoptotic markers in a time dependent 
way. A NPsD concentration of 25 µg/ml induced a significantly lower expression of cleaved PARP 
(p<0.001) and pERK (p<0.01) at 48 hours of co-treatment. The level of caspase 3 decreased 
according to dose and time of exposure to NPsD, in a significant way in comparison to CDDP 
alone, both at 24 and 48 hours of co-treatment (p<0.001). 
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Fig. 4.67. Western Blot after SDS-PAGE and densitometric analysis of key proteins related to 
apoptosis (with HSP-70 as standard marker) in OC-k3 cells pre-treated for 24 hours with NPsD (25 
and 50 µg/ml), then co-treated with CDDP 13 µM and the same NPsD concentrations for 24 and 48 
hours. Bars represent standard errors. Asterisks indicate significant values in comparison to CDDP 
13 µM (* = p<0.05; **=p<0.01; ***p<0.001). 
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Based on the results of protection tests with NPsD against CDDP in OC-k3, other tests were 
performed by ultra high performance liquid chromatography (UHPLC), in order to obtain 
quantitative data on concentration of the pharmacological drug released along time by NPsD in 
cells, using the NPsD concentrations able to exert a protective effect in co-treatments. 
Starting from a given amount of NPsD, the analyses by UHPLC allowed to obtain the concentration 
of the drug inside NPsD: at the protective concentration of NPsD 50 µg/ml, about 38 ng/ml of 
conjugated dexamethasone are released. 
The amount of nanoparticle-conjugated drug released and internalized when cells were treated by 
NPsD was analysed by UHPLC and compared to that in OC-k3 cells treated with a corresponding 
amount of drug alone at 24 hours of treatment (Fig. 4.68). After 24 hours the culture medium, the 
cell lysate and the cellular pellet were analysed in the treated cells lysate. The results showed that 
the amount of dexamethasone detected after 24 hours in cells treated with NPsD was significantly 
higher (p<0.001) in comparison to those treated with the drug alone. 
 
 
Fig.4.68. Amounts of dexamethasone (ng/ml) measured by ultra high performance liquid 
chromatography (UHPLC) in extracts of OC-k3 cells treated for 24 hours either with NPsD 50 
µg/ml or with a corresponding amount of dexamethasone only for the same time. Bars represent 
standard errors. Asterisks indicate significant values between extracts treated with NPsD and treated 
with dexamethasone only (***=p<0.001). 
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The time-release profile of dexamethasone from NPsD 50 µg/ml after 4, 24 and 48 hours from 
treatment was also analysed by UHPLC. The results showed that the highest dexamethasone release 
occurred after 24 hours (Fig. 4.69): at that time, the drug concentration in the culture medium or in 
the cell lysate was significantly higher (p<0.001) in comparison to what observed at 4 hours. After 
4 and 24 hours of treatment, the highest dexamethasone concentration was detected in the culture 
medium and the amount was significantly higher (at 4 hours, p<0.01; at 24 hours, p<0.001) in 
comparison to what detected in the cell lysate. At 48 hours of treatment, the trend was reversed: the 
amount of dexamethasone was significantly higher in the cell lysate (p<0.01) than in the culture 
medium. 
 
 
Fig. 4.69. Amounts of dexamethasone (ng/ml) measured by UHPLC in extracts of OC-k3 cells 
treated for 4, 24 and 48 hours with NPsD 50 µg/ml. Bars represent standard errors. Asterisks 
indicate significant values between extracts treated with NPsD at different times (**=p<0.01; 
***=p<0.001). 
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5 Discussion 
 
According to World Health Organization data, in 2015 about 360 million people worldwide were 
affected by hearing loss, defined as a partial or total impairment of the hearing ability due to 
pathologies of the inner ear (5). Epidemiologic data about hearing loss also indicate a raising 
incidence rate over time: from 2005 to 2015 the number of people suffering from hearing disability 
increased by 29.5%, due to increasing people age and environmental noise levels. 
Hearing damage due to trauma, noise exposure or drug ototoxicity is irreversible because 
mammalian hair cells and cochlear neurons, responsible for elaboration and transmission of the 
auditory signal, are not able to regenerate (2, 179). 
Although several studies have investigated new pharmacological compounds to prevent or protect 
these cells from effects of ototoxic agents (180), no specific drug has been presently developed 
(135). Moreover, drug delivery (DD) of therapeutic compounds to the inner ear has to deal with 
problems such as the small size of the cochlea, its difficult access and the limited blood flow from 
systemic circulation (73). 
Nanoparticles (NPs) used as vehicle for DD in the inner ear may improve the existing therapeutic 
strategies (77), providing sustained release, increased half-life, improved drug diffusion and target 
specificity (78). 
During this study, liquid crystalline nanoparticles (LCN NPs) based on the endogenous lipid 
glycerol monooleate were developed and tested, conjugated with two different hydrophobic drugs, 
coenzyme Q10 and dexamethasone. These two compounds are currently tested for inner ear 
therapies but have limited solubility and bioavailability. The analyses have been performed in vitro 
on two different cell lines, PC12 and OC-k3, used as a model of inner ear cell populations. The 
effectiveness of NPs delivery has been verified against the cytotoxicity of cisplatin ((SP-4-2)-
diamminedichloroplatinum (II)) (CDDP), a well known ototoxic agent. 
 
5.1 Nanoparticles production and in vitro characterization 
 
Nanoparticles (NPs), artificial compounds with size lower than 1µm, may be used in research and 
clinical applications as a drug delivery (DD) system to improve the existing therapeutic strategies 
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(77). Besides the potential applications of these studies for hearing loss therapy, the cochlea is also 
a suitable model for studying the local applicationof NPs for DD, due to its isolated structure and to 
the cochlear fluid rheology that facilitate the distribution of compounds. Recently, innovative 
technical approaches for NP-based DD in inner ear have been tested, among them magnetic NPs 
(155), poly-D/L-lactic/glicolic acid (PGLA) (156), silicon NPs marked by a fluorochrome (181), 
hyperbranched poly-L-lysine (HBPL) and lipid core NPs (132). In all these studies NPs were 
applied near the round window membrane (RWM) and were detected in all parts of the cochlea 
(spiral ganglium, stria vascularis and hair cells), simultaneously releasing the conjugated drugs 
(134, 163). 
The ideal NPs should have the following properties: simple preparation processes, low cost of raw 
materials, high biocompatibility, temperature stability, integrity of the structure in a diluted media, 
high exchange surface and solid-like viscosity (30). For all the above reasons it was decided to test 
liquid crystalline NPs (LCN) based on the polar lipid glycerol monooleate (GMO). The LCN 
possess a versatile internal structure able to encapsulate both hydrophilic and hydrophobic 
compounds (90). Depending on the surrounding environment and/or the conjugated compounds, the 
LCN components may assemble in different phases, lamellar, hexagonal or bicontinuous cubic 
(100). The cubic phase is composed by a lipid bilayer arranged in a three-dimensional internal 
folding, converted into a viscous gel (103) that can be dispersed into NPs (cubosomes) in presence 
of an excess of water (182). The material exploits the properties of GMO, a widely studied lipid 
used in food, cosmetic and pharmaceutical preparations, which is nontoxic, biocompatible and 
biodegradable (99). In a diluted solution, the GMO bicontinuous cubic phase is thermodynamically 
stable and exhibits mechanical stiffness (112, 113). The specific preparation protocol of the 
cubosomes in this study is based on the method by Spicer and Hyden (103). 
The control cubosomes produced for this study (NPsA) have size about 200 nm, as previously 
reported in similar production processes (123, 183), exhibit the typical cubic-like structure and have 
a high sample homogeneity indicated by the low polydispersity index (PDI). They also exhibit a 
slight negative external charge (about 20 mV), a relevant parameter preventing the aggregation of 
particles when dispersed in a solution. Although positively charged cubosomes may be better 
detected when used in experiments in the cochlea (135), they exhibit a higher toxicity on cochlear 
tissues, therefore the negative charges ones were chosen for this study. The stability of particles in 
aqueous solution was verified by monitoring their physical chemical parameters for a period of two 
months, along which no significant variation was observed. 
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As reported in literature, cubosomes may be combined with numerous compounds for DD, among 
which peptides (98), proteins (114, 119, 121, 122) and drugs(123-126). Previous studies also 
showed that the inclusion of hydrophobic compounds in a cubic bicontinuous phase induced a shift 
to an hexagonal phase(98, 113, 183). The effects of different cubic or hexagonal structures of liquid 
crystalline NPs used for DD in cells, bacteria or organs are still under investigation (98, 184). This 
interesting property has been observed in the present study by adding two hydrophobic drugs, 
coenzyme Q10 (CoQ10) and dexamethasone, to the NPs preparation process. The resulting NPs, 
respectively called NPsQ and NPsD, showed a roughly hexagonal shape when observed at the 
transmission electron microscope (TEM). The physical chemical analyses of NPsQ and NPsD 
yielded very similar results to those of NPsA, and the data of the toxicity tests in vitro were 
compared with those of NPsA to verify whether the structure shifts could yield different results. 
Concerning the numerous studies on nanomaterials for therapeutic applications (115), few of them 
have analysed the possible toxic effects of NPs and the outcome of treatment of cells with 
cubosomes (185, 186). According to the results obtained in this study, the viability assays on both 
OC-k3 and PC12 cell lines, performed with the three types of NPs, generally show that these 
nanoparticles cause a dose dependent effect on cells, as reported for similar NPs formulations (131, 
183). However, the tolerance of OC-k3 and PC12 cell lines towards NPs appears very different. 
These results agree with previous reports showing that the in vitro toxicity of NPs is influenced by 
size, proliferation and embryonic origin of the selected cell lines (187, 188). 
The NPs were tested on PC12 cells at concentrations 0-200 µg/ml for 24 and 48 hours. Both NPsA 
and NPsQ induced an increase in cell viability, significant for concentrations 50-100 µg/ml at 24 
hours and for 25-125 µg/ml at 48 hours. However, NPsD caused toxic effects on PC12, inducing a 
significant decrease of viability at concentrations 13-25 µg/ml at 24 hours and 13-75 µg/ml at 48 
hours, a recover at values similar to untreated controls at 100 µg/ml and a significant toxicity at 
higher concentrations. On OC-k3 cells, NPs were tested at concentrations 0-150 µg/ml, again at 24 
and 48 hours and the viability assays yielded similar results for NPsA, NPsQ and NPsD. All NPs 
induced a comparable dose dependent decrease of cell viability, significant from 50 µg/ml onwards. 
A phase transition from cubic to roughly hexagonal phase was observed in both NPsQ and NPsD, 
therefore the different results obtained on PC12 and OC-k3 support the hypothesis that these 
differences are unrelated to the physical chemical structure but are due to the conjugated drug. The 
effects on DD of NPs phase transitions have not been further investigated in this study, but this 
interesting point deserves supplementary research in the future. 
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The dexamethasone effects described in literature are controversial and change according to the 
organ or cell line tested (68, 70, 189, 190). The molecular tests performed in this study confirm the 
toxic effects of NPsD on PC12, therefore it was chosen to interrupt the dexamethasone treatment on 
this cell line. 
The analysis of cell cycle in PC12 cells treated with NPsA and NPsQ at concentrations up to 100 
µg/ml did not reveal significant differences in the distribution of cell populations in comparison to 
untreated controls, therefore in PC12 the increment of viability was not apparently related to 
alterations of the cell cycle but only to a normal cell proliferation rate. The same results were 
obtained in OC-k3 cell line treated with all types of NPs, with no significant differences among cell 
population distribution for NPs concentrations between 0 and 50 µg/ml. 
The morphological analyses with fluorescence microscopy, conducted by treating the cells with 
NPs tagged with rhodamine B, allowed to verify the interactions of NPs inside cells and track them 
over time. The uptake of fluorescent NPs occurred 4 hours after treatment for OC-k3 cells and 8 
hours after treatment in PC12 cells. The time difference in NPs uptake between the two cell lines 
could be related to different viability cell responses and could also depend on NPs-cell membrane 
interactions, since the two cell lines have a different composition of phospholipid and membrane 
proteins (187, 188). The NPs uptake appeared dose dependent and the clearest and strongest signals 
were acquired 24 hours after treatment, although a quantitative analysis of the fluorescent signal 
was not performed. Several fluorescent spots could be identified inside the cells, suggesting that 
NPs do not self-aggregate. These results confirm that NPs are able to deliver the conjugated 
compound inside the cells, as previously reported (183, 191). The exact location of the dye could 
not be identified, but there are literature reports showing that rhodamine dyes tend to associate with 
mitochondria in living cells (192). 
The interactions of NPs with cells and the dose dependent responses led to investigate the 
morphological and molecular responses of cells to the treatment. Cells were observed by 
fluorescence microscopy in presence of cytoplasmic and nuclear morphological markers. The 
results showed that in cells treated with high doses of NPs (75 and 200 µg/ml for PC12 and 25 and 
50 µg/ml for OC-k3), a dose dependent formation of numerous intracellular vesicles and a cell 
swelling could be detected. Although the type of vesicles was not investigated in detail ,it is 
possible to advance the hypothesis that they are produced by exocitosis. An exocytotic process of 
NPs from the cell in vitro depending on particle doses and on proteins in the culture medium has 
been recently described (193). The authors indicate three possible exocytosis mechanisms: 
lysosome secretion, vesicle-related secretion and non-vesicle-related secretion. The dose dependent 
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vesicle formation observed in this study has not been investigated in detail, but it could be a cell 
mechanism to prevent osmotic stress death due to high concentration of NPs. Other morphological 
analyses were performed in this study to verify whether osmotic stress in the cell could induce cell 
death by apoptosis. A typical marker of the initial step of apoptosis is phosphatidylserine (PS), a 
lipid component of the cell membrane that can be tracked by annexin V fluorescent marker. The 
analyses of OC-k3 treated with 50 µg/ml of all types of NPs, and of PC12 treated with 100 µg/ml of 
NPsA and NPsQ did not reveal an increased exposition of PS in comparison to untreated controls. 
The analyses of the cytoskeleton of the two cell lines by the specific marker phalloidin at the same 
NPs concentrations did not show any alteration or degradation in the cytoskeleton. The nuclei 
stained with 4’,6-diamidino-2-phenylindole (DAPI)did not appear multi-lobed and no chromatin 
degradation or cell swelling were observed on both cell lines. 
These results suggest that the cells underwent a dose dependent stress while treated with NPs, but 
NPs were not able to trigger cell apoptosis. To verify this hypothesis, the RNA and protein lysate 
from cells treated with all types of NPs were analysed by quantitative PCR (RTqPCR) and Western 
blot to investigate the expression of key markers related to the apoptotic process. Few data are 
presently available in literature about the molecular effects of treatment with non-conjugated GMO 
NPs of cells and organs. Recently it has been shown that Chinese hamster ovary (CHO) and human 
lung adenocarcinoma cells (A549) exposed to GMO NPs show in the first four hours after treatment 
a significant increase in expression of some apoptosis markers, such as interferon α (IFN-α) and 
BAX. An overexpression of the oxidative stress marker heme oxygenase 1, but not of glutathione 
reductase, was also observed in these cell lines. The expression of these genes decreased after 24 
hours of treatment, returning to control levels (183). 
The results in the present study indicate a higher expression over time of the genes investigated: 
after 24 and 48 hours of treatment, some of the analysed transcripts were still overexpressed in 
comparison to controls. In PC12 cells treated with NPsA a significant increase in expression of 
caspase 8 and caspase 9 was observed at 25 µg/ml after 24 hours and 75 µg/ml after 48 hours. At 
the same concentrations caspase 3 after 48 hours while BAX was significantly overexpressed only 
at 75 µg/ml at 48 hours. On the contrary, the treatment with NPsQ induced a significant increase 
only of caspase 9 after 48 hours. In OC-k3 cells the treatment with NPsA induced an 
overexpression dose and time dependent of caspases 8 and 3, Bid, BAX and p53. The level of 
caspase 9 was lower than in controls. In treatments with NPsQ ,the transcripts were less expressed 
than with NPsA, except for caspase 3 which was significantly overexpressed over time. A similar 
pattern of reduction in gene expression was observed in treatments with NPsD, in which all 
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transcripts were expressed at the same level of controls or lower, except for caspase 3 at 50 µg/ml 
after 24 hours. 
The three types of NPs therefore induced different cell responses, that could be related to the 
different cell lines and their NPs uptake, and within cell lines, to the type of drug conjugated to 
NPs. According to literature data, the NPs preparation methods could also be involved. Concerning 
the NPs uptake, the results obtained in this study by RTqPCR are in contrast with the only other 
literature data available by RTqPCR analyses, reporting a down-expression of apoptotic marker 
genes after 24 hours (21). The differences could be explained by the later cell uptake in the cell 
lines tested in this study, unlike what described by other authors (132-134). 
Although qPCR analyses indicate that the treatment with NPs affected the cell environment and 
induced a stress response at mRNA level, these data were not confirmed by the subsequent 
translational analyses of some key apoptosis markers, such as ERK, caspase 3 and PARP. In PC12 
cells treated with NPsA or NPsQ at 50-100 µg/ml, none of the apoptotic marker proteins was 
overexpressed. The same results were obtained in OC-k3 treated with NPsA and NPsD at 10-50 
µg/ml and with NPsQ at 10-75 µg/ml, except for PARP, significantly overexpressed with NPsQ 75 
µg/ml after 48 hours, and phosphorylated ERK with NPsD 50 µg/ml after 48 hours. A high 
concentration of NPs had been previously associated to a higher toxicity on cells by the viability 
assay. These results agree with those of the previous morphological analyses with annexin V and 
propidium iodide (PI), performed at the same doses of NPs, indicating that no apoptotic process was 
undergoing in cells. It could therefore be advanced the hypothesis that NPs are tolerated by PC12 
and OC-k3 cells at different concentration ranges and that they could induce a specific stress 
response, according to the presence or not of the conjugated drug. Nevertheless, even when the cell 
environment is perturbed by the presence of NPs, at the tested concentrations the NPs did not cause 
any cell apoptosis. 
 
5.2 Cisplatin cytotoxicity 
 
Cisplatin (CDDP) is a widely used chemotherapeutic agent, currently administered in clinical 
practice for a broad variety of solid tumours (7). Its use in cancer therapy involves numerous side 
effects, including ototoxicity (194, 195). Clinical evaluations and in vivo studies on animal models 
have verified that CDDP ototoxicity affects the cochlear hair cells, the supporting cells, the spiral 
ganglion neurons and the stria vascularis. This drug exerts the highest damage in the outer hair cells 
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of the basal turn of the cochlea, causing cell death (26, 49, 196) and impairment of the signal 
transduction. It also induces calcium accumulation in the cells (22) and in neurons of the spiral 
ganglion causes disruption of neuronal processes, loss of the myelin sheath (197) and eventually 
cell death (198). 
In this study two different cell lines were selected for in vitro analyses as representative of inner ear 
cell populations affected by the CDDP ototoxicity: the OC-k3 cells express specific markers of 
epithelial cells, auditory sensory cells and supporting cells (169), and the PC12 cells may 
differentiate into nerve cells when exposed to nerve growth factor (174). Because of their 
properties, both cell lines have already been used for investigations concerning exposure to cisplatin 
(177, 199). The results of the present study generally agree with previous data: CDDP causes a dose 
and time dependent cytotoxicity (13, 170, 177) and cell death by apoptosis (200, 201). The toxicity 
of the chemotherapeutic agent was higher on PC12 cells than on OC-k3 at the same dose. At 5 µM, 
CDDP was significantly toxic on PC12 after 24 hours and on OC-k3 after 48 hours; at 13 µM 
CDDP induced on PC12 cells a 80% decrease in cell viability after 48 hours, in comparison to a 
60% decrease on OC-k3 (p<0.001). In protection experiments, the value of 5 µM was therefore 
chosen as the limit CDDP concentration for PC12 cells because this concentration was already 
significantly toxic after 48 hours, and that of 13 µM was chosen for OC-k3. 
Previous studies showed that CDDP caused apoptosis by binding DNA, forming adducts (7), 
arresting the cell cycle (20), inducing ROS production (24-26) and activating both extrinsic and 
intrinsic apoptotic pathways (202). Since the three pathways to apoptosis are related to each other, it 
is likely that CDDP may be affect all of them. Moreover, different cell lines show different 
apoptosis related effects when exposed to CDDP: in differentiated pot-mitotic lines, the damage by 
CDDP is exerted mostly through the ROS pathway, but in undifferentiated or scarcely differentiated 
cells, actively in mitosis, the CDDP-induced DNA damage pathway is prevalent (30).  
Inside the cell, chloride ions allow the formation of reactive hydrated species of CDDP, but also 
nucleophilic groups containing oxygen, nitrogen or sulphur atoms with unpaired electrons, such as 
those contained in purine DNA bases, may bind to CDDP in place of chloride. Moreover, the 
hydrated CDDP form is positively charged, therefore it may electrostatically bind the negatively 
charged DNA helix (22, 202). Among the effects of cross-linking between CDDP and DNA, there 
is the arrest of the cell-cycle in G2 and the consequent triggering of apoptosis (203). The results 
obtained in this study on cell population distribution of OC-k3 and PC12 cells along the cell cycle 
generally support the above hypothesis, but in OC-k3 cells the treatment with low concentrations of 
CDDP (2.5 and 5 µM) after 24 and 48 hours did not induce a decrease of cells in G2. At these low 
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concentrations the cells could still be able to activate the DNA repairing systems, as shown by the 
increase of cells in S. The cell response to CDDP also appears to be time dependent. For example, 
in OC-k3 the viability assays showed the same damage at CDDP 5 µM after 48 hours and 13 µM 
after 24 hours, but the distribution of cells in the cell cycle was different at the two times of 
exposure: in the first case the apoptotic cells increased in number, and in the second one the cells 
accumulated in G0. 
The same trend was observed in PC12 at 5 µM. Thus, when damages to DNA become too relevant 
or irreversible, the cell arrests the repairing mechanism and triggers the apoptosis process. The 
different responses of the two cell lines to CDDP toxicity could also depend on different 
intracellular accumulation of chloride and consequent formation of the CDDP active form (204). 
Apoptosis is characterized by typical morphological changes such as cell shrinkage, cytoskeleton 
disruption, cytoplasm condensation and internucleosomal DNA fragmentation (205). As previously 
mentioned, one of the initial markers of apoptosis is PS. Both OC-k3 and PC12 treated with CDDP 
were positive to this marker at 24 hours, at concentrations 5 µM for PC12 and 13 µM for OC-k3, in 
correspondence of increasing effects of CDDP detected in viability assays. 
The irreversible DNA damages and the arrest of cell cycle are both events able to activate the pro-
apoptotic cell response, which involves numerous molecular pathways, and are also related to 
overexpression of the anti-tumour transcription factor p53 (206). The p53is a powerful upregulator 
of Bid and BAX proteins (42), which induce the release of cytochrome c from mitochondria and the 
activation of the intrinsic pathway of apoptosis (43). It has been shown that CDDP is able to trigger 
apoptosis through the extrinsic pathway, via cell surface death receptors and cleavage of pro-
caspase 8 (38). The CDDP also causes an intracellular ROS production, which may induce 
activation of the intrinsic pathway of apoptosis (30). The connection between the two pathways 
occurs when the initial apoptotic signal initiated by caspase 8 is amplified at the level of 
mitochondria, resulting in cytochrome c release and upregulation of the effector caspases 3 (202). 
These results have been verified by numerous in vitro studies on different cell lines and in vivo 
(202, 207-209). 
The expression of markers of the apoptotic process have been analysed by RTqPCR on OC-k3 cells 
and PC12: the results indicate a general overexpression of RNA transcripts of the initiator caspases 
8 and 9, of the proapoptotic factor p53, of the mitochondrial protein Bid and BAX and the effector 
caspases 3 on both cell lines. These results agree with previous studies indicating that induction of 
apoptosis by CDDP does not occur through a single signal pathway, but triggers several factors in 
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different pathways. In the present study, the expression of caspase 8 is significantly high at 5 µM 
for both cell lines and increases with dose and time of exposure to the chemotherapeutic agent. 
At CDDP 25 µM the expression of caspase 8 transcript in OC-k3 cells is lower in comparison to 13 
µM dose, probably because of activation of other pathways by the high concentration of CDDP. At 
low doses of CDDP, caspase 9 already results overexpressed in comparison to controls, but the 
difference is significant only after 48 hours of treatment with CDDP 25 µM. The higher expression 
of caspase 8 in comparison to that of caspase 9 indicates a major activation of the extrinsic pathway 
in comparison to the intrinsic one. This is however in contrast to results of previous studies in vitro 
on HEI-OC1 cells (202) in which a transient overexpression of caspase 8 in the first 6 hours of 
CDDP treatment and a shift to a prolonged overexpression of caspase 9 within the first 12 hours of 
treatment was observed. Caspase 3 results significantly expressed over time and dose of CDDP 
already at 5 µM at 24 hours on both cell lines. These results are in agreement with previous studies 
suggesting that caspase 3 is activated downstream of activation of both caspase 8 and 9. The 
transcript of p53 is overexpressed in accordance to CDDP concentration and time of exposure on 
both cell lines. The levels of Bid and BAX transcripts follow the same expression trend, indicating 
that p53 upregulates the two mitochondrial factors, in agreement with literature data (210). Overall, 
these data indicate a multifactorial apoptosis triggered by CDDP; a hypothesis could be advanced 
that apoptosis is activated on these cells mainly through the extrinsic pathway (high levels of 
caspase 8) and by DNA damages (high p53 levels), and less through the intrinsic way related to 
ROS production. These results on these undifferentiated cell lines are in agreement with a 
hypothesis suggesting that the main cause of apoptosis by CDDP in differentiated post-mitotic 
cochlear cells is related to ROS production and not to DNA damages(30). 
The results obtained by RTqPCR analyses clearly correlate with those of protein apoptotic markers 
examined by Western blot. Apoptosis induced by CDDP involves the MAPK family, and the ERK 
subfamily is relevant for regulation of cell growth and differentiation(211). It has been shown on 
HeLa cells that the activation of ERK plays a role in induction of apoptosis by CDDP (13). The 
results presented in this study support the fact that in both cell lines the significant increase of 
phosphorylated ERK is in accordance to concentration and time of exposure to CDDP. Another 
apoptotic key protein analysed was cleaved caspase 3, whose expression reflected the same trend 
observed for its transcript. The action of caspase 3 influences the protein PARP, involved in DNA 
repairing system, which is inactivated by protein cleavage directly from caspase 3 (212). The results 
of this study agree with literature data showing a significant increase in PARP and caspase 3 levels 
in cells. 
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5.3 Protection analyses 
 
It is known that the effects of cisplatin in cells have a broad spectrum and may induce apoptosis by 
activation of both the intrinsic and extrinsic pathway. The ideal protector against CDDP should then 
possess the ability to interfere with CDDP action mechanisms and prevent, block or lower its 
cytotoxic effects. In this study dealing with exogenous NPs, the first issue to be investigated was 
the interaction among cells, nanomaterials and activated pathways within the cells. The results of 
this study indicate that NPs alone induce a cellular stress at high concentrations, but the presence of 
conjugated drugs lowers the expression of stress markers, thus apoptosis is not triggered in the 
studied cell lines. 
It was therefore important to discriminate between the effects of NPs and those of CDDP treatment 
on cells, in order to avoid a cumulative toxic effect when treating the cells with both compounds. In 
order to prevent or reduce the toxic effects of CDDP, it was chosen to pretreat cells with the 
protective agents conjugated with NPs. The two selected drugs, CoQ10 and dexamethasone, exhibit 
a very low solubility and bioavailability, and have already been tested against ototoxicity induced 
by CDDP. 
Although several literature studies have focused on delivery of protective drugs in cells or organs 
including the inner ear, none of them has up to date proposed a model of study of co-treatment 
using both the toxic agent and the NPs based system on the same substrate. 
 
5.3.1 NPsQ vs CDDP 
 
The coenzyme Q10 (CoQ10) is a vitamin-like antioxidant, involved in numerous energy-producing 
metabolic pathways of cells and regulating the mitochondrial respiratory chain. It is also able to 
scavenge oxygen radicals and inhibit lipid peroxidation, preventing damages to cells and tissues 
(56-58). As a ROS scavenger,CoQ10 works by inhibiting the mitochondrial membrane 
depolarization, blocking the release of cytochrome c in the cytoplasm and the activation of the 
intrinsic apoptotic pathway (60). The CoQ10 is an ubiquitous factor, essential for cell respiration 
and other key functions; any deficiency in its availability or biosynthesis may disrupt normal 
cellular function (213). Several factors have been shown to decrease CoQ10 levels, among which 
illness, inflammation, stress and aging(214). Because of its relevant role in physiological processes 
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and its ubiquity, it has been the subject of a broad range of studies to reduce oxidative stress 
conditions, achieved by replenishing CoQ10 shortage or by administering supplementary amounts 
of it. This has occurred for example in cardiovascular diseases (215), in onset and progression of 
breast cancer (216), for neuroprotection (217) and in case of hearing loss (218, 219). The local 
administration of antioxidants has been connected with increased glutathione levels and decreased 
noise hearing loss (62). Other authors showed that the preventive application of local antioxidants 
reduced the noise induced hearing loss (63). 
Regardless of its therapeutic benefits, the delivery of CoQ10 is challenging due to its low aqueous 
solubility (<4 ng/ml), high molecular weight and thermosensitivity (220). Previous studies 
investigated the oral bioavailability increment of CoQ10 conjugated in GMO NPs in vivo (220) and 
the actual release of the drug in vitro by tracking the lipase activity (221). To date, there are no 
reports about the potential delivery to the inner ear of CoQ10 by GMO NPs. 
According to the protective effects of antioxidants on inner ear tissues (62), and to the timing for 
NPs uptake in cells detected in this study, cells were pretreated with NPsQ 24 before applying 
CDDP. Although CoQ10 is broadly used as antioxidant agent, its delivery in vitro by GMO NPs did 
not provide significant protection against highly cytotoxic doses of CDDP. The NPsQ were tested 
on PC12 at concentrations 25-75 µg/ml and on OC-k3 at 10-50 µg/ml, based on previous 
biocompatibility results by viability assays. The CDDP was tested in co-treatments at 5-25 µM, but 
a protective effect of NPsQ was obtained only against CDDP 5 µM in both cell lines. On PC12 
cells, CDDP 5 µM caused a high dose and time dependent toxicity; the results of viability assays 
showed that co-treatment with NPsQ could induce a slight recover at 75-100 µg/ml at 24 hours, and 
at 25 and 75 µg/ml after 48 hours. However, despite the recovery, the cell viability was too low 
compared to controls after 48 hours, and at 24 hours the variation was minimal. On OC-k3 cells, the 
recover from CDDP 5 µM toxicity was very low for NPsQ 10-25 µg/ml. Moreover, with NPsQ 50 
µg/ml a decreased viability of the cells was observed, probably because of a synergic effect 
between stress induced by the high NPsQ concentration and CDDP toxicity. The analysis of the cell 
cycle confirmed these results: for both cell lines co-treated with the same concentrations used for 
the viability assays, no significant difference was observed in the cell population distribution 
compared to the treatment by CDDP alone. However, in treatment with only NPsQ it was also 
observed that NPs did not induce any significant change in the cell cycle. 
The morphological analyses highlighted a better response of cells to co-treatments: with CDDP 5 
µM the number of cells attached to substrate significantly decreased, but the number of observed 
cells increased with high NPsQ concentrations. The PC12 cells appeared less deformed and with a 
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lower number of multi-lobed nuclei. On the other hand, the OC-k3 cell aspect in co-treatments 
appeared similar to that of the same cells treated with CDDP 5 µM. In analyses with annexin V-
FITC, regardless of co-treatments, numerous cells stained in green and their number increased for 
high doses of NPsQ. In these cells, the CoQ10 did not directly affect the status of the cytoskeleton, 
since cells undergoing co-treatments appeared shrunk and with shorter cytoskeleton filaments, 
typical effects of CDDP. 
No oxidative stress markers were analysed in molecular tests, but CoQ10 is known to directly 
influence the release of cytochrome c from mitochondria, blocking the cleavage of caspase 9 and3 
and therefore the intrinsic apoptotic pathway (59, 60). However, on PC12 cells the expression of 
caspase 9 was not lowered by co-treatments and the enzyme was overexpressed in comparison to 
CDDP at 24 hours with NPsQ 25 µg/ml. Caspase 3 and BAX were generally overexpressed, 
significantly after 24 hours of co-treatment. These results suggest an absence of protection from 
apoptosis by NPsQ in this cell line. All analysed transcripts were also under expressed over time: 
these results agree with those of viability assays indicating at 48 hours of co-treatment a higher 
recover of cell viability in comparison to 24 hours. The results of protein expression by Western 
blot in co-treatments indicate a dose and time dependent under expression of apoptotic markers in 
comparison to CDDP: this is in agreement with the results of analyses with NPsQ only, where, 
regardless of an overexpression of mRNA transcripts, no overexpression of the apoptotic proteins 
was observed in comparison to untreated controls. However, although a significant decrease in 
caspase 3 and PARP levels was detected in co-treatments, the expression of these proteins remained 
significantly higher than controls, indicating a high apoptotic rate. 
In OC-k3 cells, the mRNA transcripts were generally overexpressed over time in co-treatments, 
except for caspase 8 and 9. These results are in agreement with those obtained by treatments with 
NPsQ only, which were able to reduce the expression of early apoptosis markers at 24 hours in 
comparison to untreated controls. Other late apoptosis markers such as BAX, Bid and caspase 3 
were however overexpressed in co-treatments in comparison to CDDP. 
All these results suggest that CoQ10 conjugated to NPs, although able to exert a slight protective 
effect on both cell lines against CDDP damages, was not able to significantly prevent CDDP-
induced apoptosis in comparison to cells not exposed to this highly cytotoxic agent. 
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5.3.2 NPsD vs CDDP 
 
Dexamethasone is a glucocorticoid used for a broad variety of clinical therapies, and in the inner ear 
as an anti-inflammatory and antioxidant (26). Its classical systemic administration causes numerous 
side effects due to the steroid accumulation in other organs (190, 222), therefore the local 
application is preferred for therapies of the inner ear. Concerning drug induced hearing loss, it has 
been shown that preventive local applications of dexamethasone may reduce the ototoxicity caused 
by aminoglycosides in vivo (68) and reduce CDDP ototoxicity by increasing antioxidant levels in 
cells (69) and by decreasing levels of NADPH oxidase 3 (70). Dexamethasone has however a low 
solubility: in order to overcome this problem, and also to develop a more targeted local therapy and 
reduce the administered dose, this drug has been recently associated to steroid-eluting electrodes 
(223) or lipid nanoparticles (136). 
Literature data about the effects of dexamethasone are still controversial, depending on the different 
cell lines tested or on associated compounds. For example, some authors suggested that the use of 
dexamethasone in addition to antibiotic therapy against acute bacterial meningitis increased 
hippocampal neuronal apoptosis (189).These data could be related to the results of this study, in 
which dexamethasone induced a significant toxicity on PC12 neuronal cells when conjugated with 
NPs, while an opposite effect was detected on OC-k3 epithelial cells. Given the different effects on 
the two cell lines analysed in this study, the protection by NPsD against CDDP toxicity was fully 
investigated only on OC-k3 cells. 
The NPsD were tested at 10-50 µg/ml against different CDDP concentrations: they were able to 
protect against the highly cytotoxic CDDP concentration of 13 µM. In viability assays there was no 
recover after 24 hours, but after 48 hours of co-treatment a highly significant increase in cell 
viability was observed with NPsD 50 µg/ml compared to CDDP 13 µM. The analysis of the cell 
cycle confirmed that after 48 hours of co-treatment with NPsD 25-50 µg/ml, a significant increase 
was found in G2/M phase and a decrease (although not significant) in hypodiploid cell population; 
the number of cells in G0 or S did not show significant differences. A significant number of OC-k3 
mitotic cells could be observed also in morphological results with NPsD 50 µg/ml. In agreement 
with previous results, the number of adhering cells increased with co-treatments at 48 hours, the 
cells had shape and cytoskeleton similar to untreated controls and a minor number of them 
exhibited the green annexin V-FITC stain. 
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The results obtained by RTqPCR on OC-k3 cells are very promising and indicate a significant 
under-expression of all transcripts analysed, including caspase 3. Even in contrast to the results of 
viability assays, the expression of transcripts increased over time, remaining significantly lower 
than CDDP 13 µM. No oxidative stress marker was analysed in this study, but the underexpression 
of caspase 9, directly activated by intracellular oxidative stress, allows to advance the hypothesis 
that dexamethasone conjugated to NPs may protect against CDDP-induced ROS toxicity. 
Moreover, the significant low expression of caspase 8 and 3 (compared to CDD 13 µM) agrees with 
results by other authors showing that in human eosinophils the dexamethasone treatment does no 
trigger the cleavage of caspase 8 and 3 (71). It is interesting to notice that the most protective 
concentration of NPsD in morphological and viability tests is 50 µg/ml, while in RTqPCR data an 
NPsD concentration of25 µg/ml induces a lower transcript expression. It may be assumed that a 
higher amount of NPsD induces a higher cellular stress, increasing cell response through the 
expression of genes related to apoptosis, whereas the high amount of internalized dexamethasone 
actively protects against cytotoxicity caused by CDDP and allows a higher cell survival rate. These 
data agree with those of protein expression analysed by Western blot, indicating a significant 
underexpression of cleaved caspase 3, PARP and pERK in comparison to CDDP only. At protein 
levels, the most protective NPsD concentration is again 25 µg/ml. 
Based on these results, further analyses were performed to quantify the amount of dexamethasone 
released from NPsD and internalized in OC-k3 cells. The analysis by ultra performance liquid 
chromatography (UPLC) of OC-k3 treated with NPsD 50 µg/ml compared to cells treated with a 
corresponding amount of dexamethasone only (about 40 ng/ml) indicate that NPs significantly 
improve the cell uptake of dexamethasone, as previously shown in vivo (136). By tracking the drug 
release over time it was also possible to show that the highest amount of the compound was 
released in culture medium and inside cells after 24 hours from treatment, in accordance with 
observations conducted with NPs conjugated to the fluorescent dye rhodamine B and with timing 
employed in co-treatment analyses. Overall, these results clearly suggest that NPs induced a higher 
internalization of dexamethasone in cells in comparison to treatments with the compound alone. 
Based on UPLC results, it is also likely that the conjugation to NPs may protect dexamethasone 
from degradation, increasing its half-life. 
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6. Conclusions and future developments 
 
The nanoparticles (NPs) based on glycerol monooleate produced in this study are stable in the 
liquid dispersion and are able to internalize hydrophobic drugs of interest. These NPs were 
conjugated with two drugs currently used in inner ear therapies, coenzyme Q10 (NPsQ) and 
dexamethasone (NPsD). Non-conjugated nanoparticles (NPsA) tagged with a fluorescent dye 
(rhodamine B) applied in vitro on inner ear cell models, the PC12 and OC-k3 cell lines, were 
uptaken in the first 4-8 hours after treatment. The administration of NPsD on OC-k3 revealed a 
significant improvement of the delivery of the conjugated drug inside cells after 4, 24 and 48 hours 
of treatment, compared to the drug alone. On PC12 cells, NPsA and NPsQ were not toxic up to 100 
µg/ml and did not induce signs of apoptosis, while NPsD resulted toxic on this cell line at low 
concentrations. All other NPs produced were not toxic on OC-k3 cells up to 50 µg/ml and did not 
induce signs of apoptosis. 
The NPsQ and NPsD were tested in vitro to reduce the cytotoxicity of cisplatin, a antitumor agent 
causing a high dose and time dependent cytotoxicity on both PC12 and OC-k3 cells by inducing 
apoptosis. The NPs carrying coenzyme Q10 were able to induce a slight reduction of toxicity of 
cisplatin 5 µM on PC12 and OC-k3 cells after 24 and 48 hours, while NPs conjugated with 
dexamethasone were able to significantly reduce the toxicity of cisplatin 13 µM on OC-k3 cells, 
especially after 48 hours. 
Based on these promising in vitro results on inner ear cell models, the future developments could 
concern the application of NPs carrying therapeutic agents in vivo on animal models, mostly 
focusing on dexamethasone delivery. Local application of NPsD in the inner ear could improve the 
half-life and the distribution of the conjugated compound in the cochlea and lead to reduce 
ototoxicity caused by systemic treatment with cisplatin, without affecting its efficacy as antitumor 
drug. 
The NP-based system have a high potential for inner ear delivery of therapeutic drugs. Their use 
could minimize the side effects of treatments, allow a better target specificity and provide a 
sustained release of drugs in inner ear fluids. The type of NPs may be modified, different drugs may 
be carried and several formulations could be tested. The NPs could also be combined with other 
nanomaterials, such as hydrogels, to improve the local application of drugs. However, several issues 
have yet to be solved and more in vivo studies are necessary to verify NPs bioavailability and 
effectiveness before successful clinical applications. 
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